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Abstract 
 Viruses are known to be associated with 20% of human cancers. Epstein 
Barr virus (EBV) in particular is the first virus associated with human cancers. 
Here, we computationally detect EBV and explore the effects of this virus across 
cancers by taking advantage of the fact that EBV microRNAs (miRNAs) and 
Epstein Barr virus small RNAs (EBERs) are expressed at all viral latencies. We 
identify and characterize two sub-populations of EBV positive tumors: those with 
high levels of EBV miRNA and EBERS expression and those with medium levels 
of expression.  
 Based on principal component analysis (PCA) and hierarchical clustering 
of viral miRNAs across all samples we observe a pattern of expression for these 
EBV miRNAs which is correlated with both the tumor cell type (B cell versus 
epithelial cell) and with the overall levels of expression of these miRNAs.  
 We further investigated the effect of the levels of EBV miRNAs with the 
overall survival of patients across cancers. Through Kaplan Meier survival 
analysis we observe a significant correlation with levels of EBV miRNAs and 
lower survival in adult AML patients. We also designed a machine learning model 
for risk assessment of EBV in association with adult AML and other clinical 
factors. 
 Our next aim was to identify targets of EBV miRNAs, hence, we used a 
combination of previously known methodologies for miRNA target detection in 
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addition to a multivariable regression approach to identify targets of these viral 
miRNAs in stomach cancer. 
 Finally, we investigate the variations across EBV subtype specific 
EBNA3C gene which interacts with the host immune system. Preliminary data 
suggests potential regional variations plus higher pathogenicity of subtype 1 in 
comparison to subtype 2 EBV. 
 Overall, these studies further our understanding of how EBV manipulates 
the tumor microenvironment across cancer subtypes. 
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I CHAPTER I: Introduction 
I.1 Preface 
This introduction is adapted from the manuscripts and discussions contained in 
chapters II, III, IV, V and VI of this thesis. 
I.2 Introduction 
I.2.1 Epstein Barr Virus (EBV)  
 Epstein Barr virus (EBV) is part of the Herpesviridae subfamily of DNA 
viruses[1]. The Herpesviridae subfamily comprises three genus of 
gammaherpesvirus, alphaherpesviruses and beta herpes viruses, which are 
classified based on their sequence homologies (approximately 30%) and genetic 
architecture[2]. EBV is part of the lymphotropic gammaherpesvirus genus, best 
known for its ability to enter viral latency in majority of cells they infect [2].  
EBV can get transferred from one individual to another by fluid 
transmission. The virus initially infects the host’s oropharyngeal cells, in the form 
of acute infectious mononucleosis (IM). The latter can be observed in the form of 
white spots on the tonsils of the infected individual. From there, the virus gains 
access to the lymph nodes and consequently the B cells. The infected naive B 
cells will undergo differentiation in the germinal centers (GC) and differentiate to 
plasma cells. The plasma B cells will next either infect other B cells and become 
latent or infect epithelial cells, while circulating in the blood (Figure 1.1A) [3,4]. 
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At the initial point of infection, the virus exists in its lytic or acute phase. 
The virus is expressing most of its messenger RNAs (mRNAs) and microRNAs 
(miRNAs). Depending on the cell type EBV is infecting, it utilizes its glycoproteins 
and other proteins on its membrane to interact with host CD21/CR2 or integrin, 
enter via membrane fusion, and establish latency in the host cells [4,5].  
EBV has four latencies, and each latency has either its own pattern of viral 
mRNA expression or none.  These latecies are as followed: Latency III, Latency 
II, latency 0, and Latency I.  Latency I specific genes are LMP1 and EBNA1, 
while in latency II LMP1, LMP2a, LMP2b, and EBNA1 are being expressed. 
Latency 0 has no gene epression and on Latency III the virus expresses genes 
such as EBNA2, EBNA3, EBNA-LP and EBNA1. The latter genes have been 
shown to interact with host genome, and cause both epigenetic and expression 
alterations (Figure 1.1B).  
There are two subtypes of EBV. Subtype 1 EBV is the most common 
subtype across the world barring Africa (~90% across the world and 50% in 
Africa). Subtype 2 EBV is seen mainly in Africa and worldwide HIV patients (10% 
across the world and 25-50% in the Africa and HIV positive population) [6,7]. 
Although there is not much information about the pathogenicity differences of the 
two subtypes, research on the host genome of EBV positive endemic Burkitt 
lymphoma (eBL) patients has shown more oncogenic variations associated with 
the subtype 1 genome [8]. Subtype 2 genome seems to manifest in 
immunodeficient patients and the oncogenic variation profile appears to be closer 
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to EBV negative patients [8,9]. Furthermore, subtype 2 EBV seems to carry more 
repeat sequences, hence it is around 173 kilobase pairs (kb) while the subtype 1 
genome is around 171 kbs. There are also subtype specific variations observed 
across EBV genome [10].  
I.2.2 EBV and Overall Malignancies and Ailments  
 More than 95% of world's population has been exposed to EBV and 
sustain an asymtomatic infection throughout their lives [11]. EBV has been 
associated with many malignancies and ailments. Classic EBV-associated 
cancers include Burkitt lymphoma (BL), in particular eBL (85-90%, a form of non-
hodgkin's lymphoma), nasopharyngeal carcinoma (NPC, 70-80%), and stomach 
cancer(5-30%) [12–14].  
 The classic tumors associated with EBV, in which EBV was first identified, 
come from endemic Burkitt lymphomas. This cancer occurs in 5-10 / 100,000 
children in Africa and is responsible for 74% of childhood cancers in this region. 
The hallmark signature of this tumor is Myc translocation with one of the 
immunoglobulin genes (IgH) t(8;14)(q24;q32) in 80% of cases, and in the 
remaining 20% of tumors, immunoglobulin kappa (IgK) or lambda (IgL) (t(2;8 and 
t(8;22)respectively) are translocated. EBV has been linked to proliferation and 
inhibition of apoptosis of eBL tumors in many ways. One major pathway by which 
EBV facilitates tumor growth is inducing interleukin 10 (IL10), which produces 
signals to dampen the immune response in EBV infection [15]. 
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Sporadic cases of EBV positivity in tumors have been reported for lung 
cancer, esophageal cancer, colon cancer, diffuse large B cell lymphoma (DLBC), 
and acute lymphoblastic leukemia (ALL) (in childerent) [16–18]. EBV has also 
been associated with other ailments such as multiple sclerosis, lupus, and other 
autoimmune disease[19,20].  
 The mechanisms of EBV that may facilitate metastasis and tumor growth 
has been studied in various cancers. For example, EBV EBNA3C gene is known 
to interact with the enzyme induced cytidine deaminase (AID) which is involved in 
B cell hypermutation, and can affect B cell transformation in B cell lymphocytes 
[21]. Presence of virus has been associated with an increase in nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) pathways utilizing its viral 
mRNA LMP1, which has been linked to increase in the proliferation and 
metastasis when overactivated [22]. The virus has also been implicated with 
inhibition of apoptosis in tumor cells through LMP1 EBV gene interaction with 
BCL-2 host gene and in turn lead to inhibition of apoptosis in elderly diffuse large 
B cell lymphoma patients(EDLBC)[23]. Studies have shown that EBV also affects 
the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway through the 
LMP2 and LMP1 genes [24]. This pathway has been involved in apoptosis, 
proliferation, metastasis and genomic instability of its downstream targets which 
leads to cancer manifestation [24]. There are additional mechanisms proposed 
for how the virus impacts the tumor microenvironment, which will be discussed 
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further in the thesis. This evidence, illustrates that EBV is very much implicated in 
human malignancies and ailments (in particular autoimmunities).   
I.2.3 Non-coding RNAs and EBV 
 Non-coding RNAs (ncRNAs), in particular microRNAs (miRNAs), have 
been implicated in maintenance of homeostasis in the human body [25-26]. 
These RNA molecules do not encode proteins but have alternate functions in 
regulation. Some of the long non-coding RNAs (lncRNAs) can regulate 
enzymatic activity (Terra lncRNA in humans) or act as various co-factors in 
formation of protein complexes [25], with crucial roles such as silencing the X-
chromosome (XIST) [25]. Another example of these molecules are miRNAs 
which are 21 to 25 base pairs and are single stranded (ss). These molecues 
have global effects across the human body and are essential for survival. 
miRNAs are produced from a longer hairpin shaped precursor called pre-miRNA 
[26]. These precursors can also be non-hairpin shaped if the miRNA is an 
intronic miRNA. This molecule is next processed inside the nucleus by a protein 
called Drosha and then exported to the cytoplasm for further processing by 
exportin-5 (EXP-5) [26]. Further processing of the molecule is done by a protein 
called Dicer [27]. These molecules are next loaded on a protein called the 
argonaut protein (AGO) and together produce the RNA-induced silencing 
complex (RISC) [28]. This complex will only retain a single strand of RNA (either 
the 3’ or 5’ guide strand) and targets the mRNA of interest by base pairing on the 
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seed region (8 nucleotide region on the 5’ end of the miRNA), with optimal 
binding energy mainly on the accessible 3’ UTRs of mRNA [29–31]. The 
significance of this event arises when binding of this complex results in the target 
mRNA repression through translational repression or by mRNA degradation. 
mRNA translation repression inhibits initiation or elongation during protein 
translation. mRNA degradation occurs when the miRNA sequence is highly 
complementary to the target mRNA, resulting to Ago protein slice activity or by  
deadenylation [26].  
 Interestingly, the EBV genome consists of 44 miRNAs, 2 lncRNAs called 
Epstein Barr encoded small RNAs (EBERs), 1 snoRNA(ncRNAs involved in 
chemical modification of other molecules in particular ribosomal RNAs), and 
many copies of stable intronic sequence RNAs (sisRNAs, these molecules have 
only been known to be generated from the intronic repeat region of genes in EBV 
and frog oocytes) [32,33]. EBV miRNAs are transcribed from 3 regions on the 
viral genome. The 3 BHRF1 (only latency III) EBV miRNAs are produced from Cp 
or Wp promoter of the virus. These miRNAs have been shown to be involved in 
viral transformation and latency III programming of the virus [34]. The rest of the 
41 miRNAs are produced from 2 clusters called the Bart clusters, which are 
expressed from the P1 and P2 promoters (Figure 1.2) [34]. EBV ncRNAs, in 
particular miRNAs, are expressed during all viral latencies, have been shown to 
have many effects on the tumor microenvironment and have been used as 
prognostic biomarkers for survival which we will discuss in detail [34]. 
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I.2.4 Sequencing Technologies and EBV 
 After the human genome was first sequenced by Sanger sequencing in 
2001, many resources and new technology have been developed in the field of 
sequencing to make this technology cheaper and more frequently available to the 
scientific community [35,36]. There are many sequencing platforms available, 
however, they mostly follow the same principles: DNA, RNA, or small RNA 
molecules are extracted from the sample of interest, the libraries for sequencing 
are prepared using different strategies [37]. One important detail in the library 
preparation step from mRNA or small RNA sequencing (smRNA-seq) is 
eliminating the ribosomal RNA (or for small RNA smRNA-seq fragments of these 
ribosomal RNAs) before sequencing, as it represents 80% of the total RNAs [38]. 
Universal indexed adapters of the complementary DNA (cDNA) produced from 
any of the latter methodologies will bind to the sequencing platform’s flow cells 
[37]. The templates are first amplified on the surface of the flow cell, and 
sequencing is followed through continuous rounds of base incorporation (each 
base has a unique fluorescent dye) and washing of the flow cell and imaging 
[37]. The dye with the 3’OH blocker is next removed and another round of repeat 
of sequencing begins. The image files (binary base calls (BCL)) are next reverted 
to the standard file format (fastq) and depending on the study, the data analysis 
step begins.  
 The field of EBV research has been advanced by utilizing previously 
described sequencing technologies [8,33,39–41]. EBV miRNAs were first 
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identified by northern blot of the BHRF1 region and BAMH1-A rightward fragment 
region (BARTS) [42,43]. The following studies which led to identification of other 
EBV and kaposi sarcoma herpes virus (KSHV) where done utilizing sequencing 
technologies, in particular microRNA sequencing (miRNA-seq) [44]. However, 
identifying these viral miRNAs thorough standard pipelines for miRNAs 
sequencing could prove problematic in the alignment step (presence of multi 
mapping reads to human EBV), but the levels of these viral miRNAs in many 
sequencing runs is not as high as the human microRNAs, therefore they might 
be ignored in differential expression analysis [45,46]. Hence, the bioinformatics 
methodology and pipeline for detection and characterization of EBV miRNAs 
needs improvement.  
 There have been many efforts to identify the targets and relationship of 
human and viral miRNA across cancers and on the tumor microenvironment 
using computational algorithms. miRNA target determination tools are often 
utilized to identify the mRNA of these molecules from sequencing data. These 
tools often take into account criteria such as 6-8 mer seed matching qualities of 
miRNA and its target, while determining the 3’ UTR availability or measuring the 
interaction energy of the target and miRNA through which they assign a score to 
such interactions [47]. The targets with the highest scores for these predictive 
qualities are then ranked as the top hits of these miRNA, but this approach may 
neglect many targets lacking these qualities that nevertheless establish true 
interactions with the miRNA. New tools for human miRNA target identification 
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have been developed which combine statistical approaches with miRNA-seq 
data and matching mRNA-seq data to assess the true correlation of the miRNAs 
on their targets. However, these tools are mainly presented as online databases 
and designed for human, fly, and worm miRNAs [48–51]. A few tools such as Vir-
Mir db and RepTar db predict viral miRNA targets, however they mainly focus on 
miRNA target prediction based on seed matching and assessment of miRNA 
target binding energy [52,53]. There is still much-needed advancement in the 
detecting targets of viral miRNAs, such as EBV, through computational pipelines 
and tools. 
 In summary, this body of work aims to answer 4 main unanswered 
questions, in regards to EBV, cancer, miRNAs and sequencing technologies: 1) 
Is there a good method for EBV identification across cancer sequencing cohorts. 
2) Does the presence of EBV in cancer affect survival outcome of patients? 3) 
What does EBV infection, in particular presence of EBV miRNAs, in various 
cancers entail in terms of tumor microenviorment? 4) Can we detect other 
sequencing technologies such as amplicon sequencing to detect EBV variations 
across the infected populations in Africa? Overall, this thesis shows EBV 
infection has a wide range of potential affects on tumor microenviorment and 
should be further utilized as a prognostic markers for certain cancers. 
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I.3 Figures 
 
 
 
Figure 1.  1. Overview of EBV binding infection of oropharyngeal cells, B 
cells and epithelial cells and EBV life cycle. 
 A. EBV transmitted through fluid exchange, in this case saliva, between an 
infected individual and a non-infected person. EBV binds to the oropharyngeal 
cells depleted of complementary receptor 2 (CD21/CR2) through a binding 
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complex formation of BMRF1 and integrin ß1. The viral fusion/entry is through 
complex formation between the glycoprotein 42 (gp 42) and envelope 
glycoproteins H and L (gH and gL) of the virus with major histocompatibility 
molecule class II of the host (HLA-class II). Hereafter, EBV finds access to lymph 
nodes hence the naive B cell. Binding of the lytic EBV virions to the naive B cells 
is through the glycoprotein 350 (gp350) of the virus and CD21 of the host cells, 
with a similar mechanism for viral fusion through endocytosis (viral latency III) 
[1,3]. From there the virus enters the germinal centers (GC) and differentiates to 
plasma cells. The virus can circulate around the body through which it can infect 
either other B cells or epithelial cells. Note although the mechanisms of infection 
are unclear, the virus is known to infect T cells as well [54]. B. EBV life cycle. 
EBV lytic phase is followed by latency III, latency II, latency 0 and latency I.  
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Figure 1.  2. EBV genome and the viral latency genes in addition to non-
coding RNAs.  
EBV latency genes are colored blue. EBV long non-coding RNAs Epstein Barr 
encoded small RNA (EBER) transcripts, are shown in red. EBV miRNAs are 
presented in purple EBV snow RNA is shown in green. EBV stable intronic RNAs 
(sis RNAs) are shown in turquoise color.  EBV promoters are represented in 
orange. Note EBV genome is ~170kb ,and the virus has a circular DNA. Hence, 
LMP2 is observable at either side of the linear EBV genome representation 
above. 
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II CHAPTER II: EBV miRNA detection and characterization across 
cancers 
II.1 Preface: 
The methodology and content of this chapter is adapted from two publications, 
one under review and one published. The authors of these publications are M. 
Movassagh, C. Oduor, C. Forconi, A. Moormann, J. Bailey, “Sensitive detection 
of EBV microRNAs across cancer spectrum reveals association with decreased 
survival in adult acute myelocytic leukemia.”, and C. Odour, M. Movassagh, Y. 
Kaymaz, K. Chelimo, J. Otieno, J. Ongecha, A. Moormann, J. Bailey “Human and 
Epstein-Barr virus miRNA profiling as predictive biomarkers for endemic Burkitt 
lymphoma.”  
II.2 Abstract: 
 Epstein barr virus (EBV) is a Ƴ- herpes virus known to be implicated in 
various forms of malignancies. While in its latent state EBV does not express 
many messenger RNAs (mRNAs), the virus does expresse its non-coding RNAs, 
in particular Epstein Barr virus encoded small RNAs (EBER) and 44 microRNAs 
(miRNAs). The EBV miRNAs are implicated in various cancers such as 
nasopharyngeal cancer (NPC), Endemic Burkitt lymphoma (eBL) and stomach 
cancer. In order to detect and characterize these viral non-coding RNAs, we 
developed a computational pipeline for sensitive detection and characterization 
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of EBV non-coding RNAs (ncRNAs) for microRNA sequencing (miRNA-seq) data 
across 27 cancer subtypes (n of tumor samples= 8,955). We next characterized 
the viral ncRNAs in terms of pattern of expression across cancer. We find a cell 
type-specific pattern in addition to a pattern of expression driven by the levels of 
EBV miRNAs across cancers. Furthermore, based on our analysis of matching 
tumor and normal tissues miRNA-seq, we find consistently higher loads of viral 
miRNAs in the tumors than the matching tissue (n = 28 matching normal and 
tumor samples). Finally, we looked for EBV miRNA variations across cancer 
subtypes. We observe very few (n=4) variations in the seed sequence of the 
virus miRNAs. Moreover, we identified tumor specific variants on these EBV 
miRNAs as well as variants which could be observed across cancers. 
II.3 Introduction: 
 
Similar to other herpes viruses, EBV displays a latency program, where it 
only expresses certain messenger RNAs (mRNAs) and microRNAs (miRNAs) 
[55]. Overall, the levels of viral mRNAs are limited to few EBV genes (LMP1, 
LMP2 and EBNA1) in the EBV latencies 0, I and II [56]. EBV non coding RNAs 
(ncRNAs), in particular Epstein Barr virus encoded small RNAs (EBERs) and 
miRNAs are expressed at all latencies.  
The full extent of EBV’s influence in cancers has been difficult to fully 
determine using genomics and classification remains largely based on EBER 
staining of tumor samples [57]. Systematic genomic study of EBV and its effects 
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on cancer prognosis through genome and transcriptome sequencing has 
limitations due to lack of sensitivity and reproducibility [58]. Such studies possess 
problematic experimental design as EBV is not normally included in exome 
capture panels of biopsies and there has been reports of EBV positive tumors 
which do not express EBERs [57]. 
 Although, the majority of healthy individuals are positive for EBV (95%), it 
is unclear why EBV is manifested in the tumor tissue of individuals with certain 
malignancies [59]. Studies have demonstrated through EBER staining that in 
EBV associated tumors, the tumor itself is manifested as EBER positive, 
however the surrounding tissue does not show any sign of EBER positivity [60]. 
However, there have been reports of EBER negative tumors [60]. This begs the 
question: are these tumor enviorment features reflected in matching normal 
microRNA sequencing (miRNA-seq) datasets? 
 miRNAs are known to have cell type-specific patterns of expressions in 
humans and other organisms [61]. Variations on the seed regions of miRNAs are 
shown to alter the efficacy of their target mRNAs, and as a result changing the 
binding fit of miRNA and its target (this is essential for target expression 
regulation) [62]. To our knowledge the variation on viral miRNAs have not been 
investigated for EBV. Here, we aimed to investigate the pattern of expression 
and the potential variations on the seed region of EBV miRNAs. The latter is 
important as it sheds light on not only how particular EBV miRNAs can regulate 
16 
 
specific tissues the virus has infected but it can unravel if these viral miRNAs 
potentially affect their targets. 
II.4 Results: 
II.4.1 EBV Detection And Classification Across Cancers 
 To better assess the presence of EBV across the cancer spectrum, we 
examined 27 different tumor types for the presence of 44 EBV miRNAs as well 
as smaller fragments of other viral non-coding RNAs (ncRNAs) including EBERs 
(Methods, Figure 2.1 and Figure 2.2). We included miRNA-seq datasets 
encompassing a total of 8,955 individual tumors with an average of 336 samples 
per cancer (range: 19-592). The samples were predominantly drawn from the 
TCGA and TARGET datasets and we also included 19 EBV-associated endemic 
Burkitt lymphoma (eBL) tumors that our group has previously sequenced miRNA 
and mRNA (Methods, Table 2.1) [39]. Cancers as well as the other host cells 
within the tumor specimens had marked differences in EBV miRNA abundance. 
EBV presence was not solely correlated with past associations of viral positive 
tumor cells. Overall, EBV miRNAs were detected in 10.2% (n=914) of tumor 
samples with different types of cancers ranging from 1% to 89%. However, this 
does not necessarily represent infected tumor cells, given that vast majority of 
adults who are latently infected with EBV are harboring virus at low levels in 
dormant B cells. Thus, detecting low level amounts of EBV is not particularly 
unexpected, given that up to 25% of an infected cells miRNA can be of viral 
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origin rather than human origin [39]. We therefore aimed to set rational 
thresholds that would be indicative of tumor cell infection as well as levels that 
might define uncontrolled EBV-infected cells within the tumor microenvironment.  
 For this, we set 3 general groupings. We first defined a subset of cancers 
with abundant or high-levels miRNA expression ≥10,000 copies per million 
(CPM) total cellular (human and EBV) miRNAs. These are likely a result of viral 
infection and miRNA expression within tumor cells and represented 0.52% of the 
total samples examined. All of these are from cancers known to harbor EBV and 
at frequencies generally in line with previous reports based on EBER positivity: 
(63% for eBL, 7.5% for stomach cancer, and 2.2% for diffuse large B cell 
lymphoma). These samples appeared by-and-large to express the full 
complement of viral miRNAs. While concordant with EBV positive rates as 
defined by EBERs staining, these levels are likely conservative as eBL positivity 
was lower than previously reported [8]. As no samples were found with a high 
level outside of tumors with previous associations, this suggests other tumor 
types do not directly harbor the virus except potentially sporadically (Figure 2.2). 
The second level of expression we categorized as medium (10-10,000 
CPM), which could be the consequence of a low fraction of infected tumor cells, 
lower expression within tumor cells, or benign B cells harboring virus (circulating 
or tumor-infiltrating) from a poorly controlled infection [63]. Overall, 10% (n=898) 
fell within this category. In general this correlated with tumors known to have 
significant lymphoid infiltrates or components such as gastrointestinal tumors. 
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Finally, 88% (n=7863) of samples had low to absent EBV miRNA expression 
levels (<10 CPM). Such low levels likely represent EBV-negative tumors within 
an individual who is either uninfected or more commonly has a well-controlled 
infection. This threshold of 10 CPM is supported as tumors lacking previous 
EBV-associations and minimally associated lymphoid-derived components (i.e. 
potential for infected B cells). This includes tumors such as Wilms tumor, adrenal 
gland carcinoma where none of the samples examined surpassed the 10 CPM 
cutoff. This level conservatively suggests that less than 1 in 100,000 cells are 
infected with EBV presuming viral miRNAs are 25% of total cellular content 
[64,65]. 
II.4.2. Pattern of miRNAs and EBERs Across Cancer Subtypes 
To investigate the pattern of small RNA expression across cancers, we 
performed principal component analysis (PCA) to find correlated patterns of 
expression for the EBV miRNAs and EBER fragments (Figure 2.3A). We 
examined only samples with measurable EBV content (≥10 CPM). The first three 
principal components (PCs) accounted for 90% of the variation (Figure 2.3A). 
PC1 and PC2 demonstrate two distinct clusters of B cell derived (pink) and 
epithelial (green) apart from the majority of samples. The eBL and diffuse large B 
cell lymphoma fell into the B cell cluster while high level gastric and esophageal 
cancers fell in the epithelial cell cluster. Most samples fell on a continuum defined 
by PC1 which appear to correlate with the absolute amount of expression. We 
also compared the expression from these two clusters more closely and we could 
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identify EBV miRNAs which are expressed in higher levels in epithelial cells in 
comparison to B cells or vice versa (Figure 2.2B). These viral miRNAs are, ebv-
mir-bart8-3p, ebv-mir-bart-7-3p and ebv-mir-bart22, ebv-mir-bart10-3p and have 
been linked to epithelial cell cancer progression and development [66]. EBV 
miRNAs in the B cell cluster, were ebv-mir-bart11-3p, ebv-mir-bart-17-3p and 
ebv-mir-bart19-3p, in addition to ebv-mir-bart19-5p. Ebv-mir-bart8-5p, ebv-mir-
bart7-3p, and ebv-mir-bart11-5p were expressed in both B cell and epithelial 
cells. We additionally confirmed the cell type specifity of these population by 
looking at the mRNA expression differences between these two groups and 
observed increase in the epithililal markers ACE and A33 (p<0.01 and q<0.01) in 
the epithilial group and increase of the B cell markers CD19 and CD22 (p<0.01 
and q<0.01) in the B cell group. Furthermore, we investigated miRNAs expressed 
at above the 1000 CPM threshold which were cell-type specific. These miRNAs 
likely have consequence in tumor environment due to their high levels of 
expression [67](Figure 2.3C). The latter data suggested not only a good portion 
of tumor samples express EBV miRNAs and EBERs but also these viral small 
RNA signatures may be cell-type dependant across cancer subtypes. 
II.4.3 EBV miRNA and EBER Load In Tumor Versus The Matching Normal 
Tissue 
 In order to identify the differences between the EBV positive tumors 
versus the matching normal tissue, we looked across 243 tumors with matching 
normal tissue from The Cancer Genome Atlas (TCGA). We next utilized our 
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pipeline for EBV positive sample detection and investigated those tissue with 
either EBV positive tumors, EBV positive normal tissue or both (>10 CPM). We 
identified 28 EBV positive cases (in tumor or normal tissue) of which 23 were 
from the stomach cancer cohort, 3 from lung squamous carcinoma, 1 from lung 
adenocarcinoma and 2 from kidney and renal cell carcinoma cohorts. We next 
identified the overall tumor burden for tumor versus normal tissue on average 
(Wilcoxon rank test, P=0.025) (Figure 2.4A). Overall the average level of EBV 
miRNA was higher in the tumors than the normal tissue. Next, we investigated 
the levels of EBV miRNAs expression in relation to the matching normal tissue ( 
Figure 2.4B). In most samples the EBV tumor levels were higher than the 
matching tumor(P=0.01558, Wilcoxon rank test for the overall trend of tumor 
being higher than matching normal tissue). We also investigated if we can 
observe any EBER positive normal matching tissue and if so what are the status 
of the tumor tissue in terms of EBER expression. Consistent with the literature 
we found no EBERs expressed in the matching normal tissue in our sample set 
[60]. Overall it seems the that tumor tissue burden for the most part is higher than 
the matching normal tissue and the EBERs are only expressed in the tumor 
microenvironment. 
II.4.4 EBV miRNA Variations 
 Variations on the miRNAs have been associated alterations on the 
effectiveness of the miRNA and target mRNA correlations as well as alterations 
in drosha processing of the particular miRNAs [68]. Hereafter, we investigated if 
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there were EBV miRNAs which retained seed region variations. Through our 
pipeline, we identified 20 variations. Of which 4 were located on the seed region, 
and none had been characterized in prior scientific literature. 3 of 4 miRNAs had 
more than one variation on other regions of the miRNA across cancers in 
multiple samples (Table 2.2). However there were a good number of variations 
on the regions of the miRNA, this is logical as these variants would not affect the 
miRNA target interactions as much [69]. 3 out of the 4 base change on the seed 
regions were C>U, which although requiring further investigation but might be a 
result of RNA-editing [70].   
II.5 Discussion 
Detection of EBV positive status of the tumor patients through viral 
miRNAs, seems logical, as not only the viral miRNAs are always expressed but 
EBER staining is not always an option. Here, we develop a bioinformatics 
pipeline for identification of EBV positive tumors through miRNA sequencing. We 
have used ubiquitously-expressed EBV miRNAs as a sensitive metric not only to 
detect but also to quantify the virus within tumors from a wide variety of cancers 
in order to better understand this pathogen’s role in oncogenesis. As EBV is a 
prevalent chronic infection we set reasonable cutoffs to differentiate tumors 
bearing the virus (high levels), uncontrolled infection of normal and/or a small 
proportion of tumor cells (medium levels), and well-controlled or uninfected 
individuals (low or absent levels). In general, our analysis supported that EBV 
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within tumor cells, where high levels are expected, is limited to previously defined 
associations. What was unexpected was the amount of expression at medium 
levels suggesting that EBV may be uncontrolled with in the patient or harbored 
within the tumor microenvironment. In general, the latter also correlated with 
tumor types known to contain higher proportions of tumor infiltrating lymphocytes.   
Through our analysis we identified expression patterns of miRNAs 
correlated with the origin cell type and suggests that viral patterns of miRNAs 
may possibly be leveraged to help define levels of B cell versus epithelial 
infection within biopsies. The significant B cell specific EBV miRNAs were ebv-
mir-bart11-3p, ebv-mir-bart-17-3p and ebv-mir-bart19-3p, and ebv-mir-bart19-5p. 
ebv-mir-bart11-3p, have been continuously found in the blood of lymphoma 
patients and has been suggested to be used as a marker for lymphomas [71]. 
Wnt pathway has been proven impactful for proper development and 
differentiation of B cells, in fact there have been many reports of lymphoma 
appearances in association with mutations or deregulations on Wnt signaling 
pathways [72]. ebv-mir-bart-17-3p and ebv-mir-bart19-3p have been linked to 
targeting important players in Wnt signaling pathway [66]. The latter could intern 
attenuate lymphomas, hence the high prevalence of these viral miRNAs in B cell 
lymphoma samples. ebv-mir-bart19-5p has been reported to downregulate LMP1 
expression, LMP1 and LMP2 genes are the major proteins regulating the latency 
1, and 2 which is the most common latency observed in epithelial cells hence it is 
no surprise that it is not as much expressed in epithelial cells as B cells. We also 
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found clear epithelial specific viral miRNA expression, these are ebv-mir-bart8-
3p, ebv-mir-bart-7-3p and ebv-mir-bart22, ebv-mir-bart10-3p and ebv-mir-bart6-
3p. Ebv-mir-bart8-3p, ebv-mir-bart7-3p, ebv-mir-bart10-3p have been shown to 
increase the aggressiveness of NPC tumors by increasing the Epithelial to 
mesenchymal cell transition of the cancer [73–75]. ebv-mir-bart22 has been 
observed to suppress LMP2 expression to protect the infected cells from 
immunological response [76]. This viral miRNA is shown to be increased in EBV 
latency II epithelial gastric tumors, which is concordant with the tumor cell type 
latency [77]. It will be interesting to further investigate this EBV miRNA in terms 
of its targets and possible self regulation mechanisms. We also show that certain 
viral miRNAs seem to be constantly expressed on both B cells and epithelial 
cells. ebv-mir-bart8-5p, ebv-mir-bart7-3p, and ebv-mir-bart11-5p are amongst 
these EBV miRNAs. Further investigation of roles of the latter EBV miRNAs can 
provide further knowledge about common mechanisms of EBV maintenance in 
the host which could be answered in the future studies.  
We further investigated the presence of EBV miRNAs in the matching 
normal tissue of tumor samples samples described. In agreement with literature 
we found none of the 28 matching normal samples as EBER positive. 
Furthermore, through statistical testing we observe the EBV miRNA burden in the 
tumor tissue is significantly more than the matching normal tissue. The latter 
could have several explanation, depending on the type of the tumor, most tumors 
have angiogenesis, hence more blood flow. The additional blood flow might 
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induce the lytic reactivation, hence more EBV burden [78]. There might be other 
possibilities for EBV as the causal agent for some tumors [21]. Further 
investigation of the latter in a larger EBV positive matching tumor and samples, 
can be useful to test these hypothesis. 
Finally understanding the effects of EBV miRNA seed changes on their 
targets and how these variations occur would be interesting for future studies. 
Additionally, investigating if these variations are made by host machinery as a 
line of defence by chance or selective pressure on the virus would be the future 
direction for further comprehending the consequences of having variations on 
EBV miRNA [10].  
We believe in the absence of EBER staining, use of miRNA-seq and our 
pipeline for identifying EBV positive tumor samples is a robust and reliable 
method. Our pipeline can be adapted to detect and investigate other viral 
miRNAs as well. Furthermore, it is only logical to investigate these EBV miRNAs 
as they are active at all times of viral lytic and latent phase and might have 
potential for vaccine design, prognostic markers for survival analysis and overall 
tumor microenvironment fluctuations. 
II.6. Materials and Methods: 
II.6.1. Tumor Sample Selection and Analysis  
Tumor miRNA-seq and associated clinical data was obtained from The 
Cancer Genome Atlas (TCGA) (https://cghub.ucsc.edu) and Therapeutically 
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Applicable Research to Generate Effective Treatments (TARGET)( 
https://ocg.cancer.gov/programs/target) projects through dbGaP (Project #13089) 
and combined these with miRNA and our RNA sequencing of eBL from Western 
Kenya (dbGaP accession number phs001282.v2.p1) [39]. For each tumor type 
up to 592 miRNA tumor samples were chosen preferentially selecting those with 
available mRNA-seq [79]. Overall, a total of 8,955 miRNA samples were 
analyzed. NPC was not assessed due to the lack of available public data 
containing viral miRNAs. The 243 matching normal and tumor samples were 
selected from the BROAD GDAC Firehose https://gdac.broadinstitute.org/. 
II.6.2. Detection and Quantification of EBV miRNAs 
The miRNA bam reads were extracted by bedtools [80] and adapter 
sequences removed using Cutadapt-1.9.1. The trimmed reads were then aligned 
simultaneously to the human (HG19) and EBV reference genomes (NC_007605) 
to detect best placements using Burrows-Wheeler Aligner (bwa-0.7.17). This 
alignment was done with recommended miRNA-aligning parameters including 
zero mismatch for the seed of 8 base pairs, this protocol was optimised for 
miRNA-seq but additionally detected other viral ncRNAs including EBERs [81–
83]. To remove human contamination such as cross mapping human miRNAs, 
only miRNA alignments that best aligned to the EBV genome were retained. We 
allowed for multiple best placements within the EBV genome so as not to exclude 
miRNAs arising from the repetitive regions. Specific miRNAs and small EBER 
fragments were then quantified based on their defined genomic locations 
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(miRBase version 22) as copies per million (CPM) using bedtools and in-house 
parsing scripts [80,84,85].  
II.6.3. miRNA Variation Calls 
For variation calls on miRNAs, we allowed for 1 or 2 variations across 
while aligning our miRNA to the EBV subtype 1 genome (NC_007605). Variant 
on the EBV miRNAs were called using SAMtools [84]  and VCFtools 
(version/0.1.11) [86]. Variants were filtered to minimize false positive calls 
requiring a minimum base quality (phred score) 20, a minimum mapping quality 
of 20, and a minimum of 10 supporting reads for a variants. 
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II.7 Figures 
 
Figure 2.  1. Pathogen detection and EBV miRNA characterization 
bioinformatics pipeline. 
TP represents the primary tumor samples and NT represents the matching 
normal tissue samples. TARGET stands for Therapeutically Applicable Research 
to Generate Effective Treatments database,TCGA stands for The Cancer 
Genome Atlas nad dbGAP stands for the NIH database for genotypes and 
phenotypes. Bedtools and BWA are bioinformatics tools for data processing as 
described in detail in methods section. For details on the bioinformatics EBV 
detection pipeline refer to methods section. 
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Figure 2.  2. EBV microRNA(miRNA) quantitative expression across 
cacners.  
In general, the total viral miRNA load at the highest levels (≥104 CPM) were 
observed only in tumors previously associated with harboring the virus (pink), 
which correlate with reported proportions of viral positive tumors in the literature. 
Previously unassociated tumors (green) posses viral miRNA levels only at 
intermediate (101-104 CPM) or low (<101 CPM) levels. Gastric tumors were 
interesting in that a majority (69.5%) fall within in the medium category 
suggesting an association with EBV beyond simple viral infection of the tumor in 
the 10% at high levels. The y-axis represents log10 counts of viral miRNA per 
total human and viral miRNA aligned to their respective genomes. The dashed 
lines separate the defined categories of viral miRNAs based on expression 
designated expression levels and and diamond lines denote median expression 
levels. 
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Figure 2.  3. PCA on relative expression of EBV miRNA of EBV positive 
samples.  
A. PCA1-3 represented 90% of the variance across samples. The red and purple 
circles includes tumor samples which possibly have B cell origins represented by 
PC2. The green circle encompassed tumor samples with epithelial origins (PC1). 
Samples shown by blue circles were the samples separating PC1 B cells tumors 
(red circle, and purple circle) and epithelial samples ( green circle). B. Heatmap 
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of hierarchical clustering of the samples circled in Fig. 2A in terms of patterns of 
viral miRNA expression in fraction of reads per million (FRPM). C. Bar plots 
represented cell type-specific patterns of viral miRNAs expression across 
samples. Each bar represented average fraction of EBV miRNA expression. Note 
only P-value significant EBV miRNAs (P<0.05 wilcoxon rank test with bonferroni 
correction) were shown with above average fraction of 0.03 per miRNAs across 
samples. 
 
 
 
 
 
 
 
 
 
 
 
31 
 
  
Figure 2.  4. Overall EBV miRNA and EBER burden for matching normal and 
tumor samples.  
A. Difference between tumor (high in tumor gold) and normal (high in normal 
blue) of samples with either normal or the matching tumor >10 CPMs. The P-
value is estimated based on paired wilcoxon rank test across samples. As shown 
in the figure legend NT stands for normal matching tissue, TP stands for 
matching tumor tissue. STAD is stomach cancer, KIPAN is Kidney renal papillary 
adenocarcinoma and LUAD and LUSC are lung adenocarcinoma and lung 
squamous cell carcinoma cohort respectively. B. Average tumor burden in NT 
(matching normal ) and TP ( matching tumor). The P value is calculated by Chi-
square test. 
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II.8 Tables	
Cancer Total Negative Positive Medium EBV Level 
High EBV 
Levels 
Acute Myeloid Leukemia, Adult 103 88 (85%) 15 (15%) 15 (15%) 0 
Acute Myeloid Leukemia, Pediatric 263 247 (94%) 16 (6%) 16 (6%) 0 
Adrenal Gland Cancer 95 94 (99%) 1 (1%) 1 (1%) 0 
Bladder Carcinoma 456 412 (9%) 44 (1%) 44 (10%) 0 
Brain Cancer 501 491 (98%) 10 (2%) 10 (2%) 0 
Breast Cancer 479 469 (98%) 10 (2%) 10 (2%) 0 
Cervical Cancer 307 292 (95%) 15 (5%) 15 (5%) 0 
Colon Adenocarcinoma 462 368 (8%) 94 (2%) 94 (2%) 0 
Diffuse Large B Cell Lymphoma 45 30 (67%) 15 (33%) 14 (31%) 1 (2%) 
Endemic Burkitt Lymphoma 19 2 (11%) 17 (89%) 5 (26%) 12 (63%) 
Esophageal Cancer 186 135 (73%) 51 (27%) 49 (26%) 2 (1%) 
Head and Neck Cancer 528 457 (87%) 71 (13%) 71 (13%) 0 
Kidney Papillary Cell Carcinoma 291 289 (99%) 2 (1%) 2 (1%) 0 
Kidney Renal Clear Cell Carcinoma 537 532 (99%) 5 (1%) 5 (1%) 0 
Liver Carcinoma 377 366 (97%) 11 (3%) 12 (3%) 0 
Lung Adenocarcinoma 522 487 (93%) 35 (6%) 35 (6%) 0 
Lung Squamous Carcinoma 504 442 (88%) 62 (12%) 63 (12%) 0 
Ovarian Cancer 592 570 (96%) 22 (4%) 22 (4%) 0 
Prostate Cancer 499 496 (99%) 3 (1%) 3 (1%) 0 
Rectal Adenocarcinoma 161 120 (75%) 41 (33%) 40 (24%) 0 
Sarcoma 124 121 (98%) 3 (1%) 3 (2%) 0 
Stomach Adenocarcinoma 456 105 (23%) 351 (76%) 317 (68.5%) 34 (7.5%) 
Testicular Cancer 134 130 (97%) 4 (2%) 4 (3%) 0 
Thymoma 124 122 (98%) 2 (2%) 2 (1.6%) 0 
Thyroid Cancer 503 501 (99.5%) 2 (0%) 2 (0.5%) 0 
Uterus Cancer 548 536 (98%) 12 (2%) 12 (2%) 0 
Wilms Tumor 139 139 (100%) 0 0 0 
Table 2. 1.EBV miRNA levels for each cancer type.  
Positive samples are samples with ≥10 counts per million (CPM) of viral miRNA 
and EBER expression. Negative samples are those with ≤10 CPM of viral 
miRNA and EBERs levels.  Green lines signify cancers samples previously 
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associated with Epstein Barr Virus (EBV). The first number on each cell of  “#S of 
amples with medium/high EBV level”, represents the number of samples and the 
second number in the parenthesis reports the percent of the latter samples. 
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miRNA Name Number of Different Variation 
Number of 
Samples 
Containing The 
Variation 
Cancer Types 
With This 
Variation 
Number of Seed 
Region Variation 
ebv_mir_bart4 1 1 1 0 
ebv_mir_bart1_3p 1 1 1 0 
ebv_mir_bart18_5p 1 1 1 0 
ebv_mir_bart18_3p 2 3 3 1 
ebv_mir_bart7 1 4 1 0 
ebv_mir_bart8 1 15 1 0 
ebv_mir_bart9 1 9 1 0 
ebv_mir_bart22 1 2 1 0 
ebv_mir_bart10 3 7 3 1 
ebv_mir_bart19_5p 3 7 2 1 
ebv_mir_bart20_5p 1 2 1 0 
ebv_mir_bart13 1 8 2 0 
ebv_mir_bart14 1 1 1 1 
Table 2. 2. Pan Cancer EBV miRNA variations 
EBV miRNA variations across 27 cancers. Number of variations represent individual 
variations on particular EBV miRNAs.  
 
 
 
 
 
 
 
 
 
35 
 
III CHAPTER III: Sensitive detection of EBV microRNAs reveals 
association with decreased survival in adult acute myelocytic leukemia 
III.1 Preface: 
The methodology and content of this chapter is adapted from a publication under 
review. The authors of this publication are M. Movassagh, C. Oduor, C. Forconi, 
A. Moormann, J. Bailey, “Sensitive detection of EBV microRNAs across cancer 
spectrum reveals association with decreased survival in adult acute myelocytic 
leukemia.” 
III.2 Abstract: 
Epstein Barr virus (EBV) is an etiologic agent involved in numerous 
human cancers. After infecting the host EBV establishes a latent infection with 
low levels of messenger RNA and protein expression evolved to evade immune 
recognition. Conversely, EBV microRNAs (miRNA) are expressed ubiquitously 
and abundantly within infected cells. Their role in tumor progression and patient 
outcomes is not fully understood. Here, we apply our bioinformatics pipeline for 
quantitative EBV miRNA detection to examine sequencing data of 8,955 
individual tumor samples across 27 tumor types representing the breadth of 
cancer. In addition to known associations, we find intermediate levels of EBV 
miRNA in other cancers, notably gastric cancer. Most importantly, we uncover an 
association of intermediate levels of viral miRNA with decreased survival in adult 
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acute myeloid leukemia (AML) patients [P=0.00013]. Prognostic modeling 
suggests that EBV miRNA levels represents an independent risk factor for 
patient outcomes. Furthermore, we explore differences in expression between 
elevated and low viral loads in adult AML tumors finding that EBV positivity is 
associated with proinflammatory signals. Together, given no associations were 
found for pediatric AML, our analyses suggest EBV positivity has the potential for 
being a useful prognostic biomarker and may represent a surrogate measure of 
immune impairment in adult patients.  
III.3 Introduction: 
Epstein Barr virus (EBV) is linked to 1.5% of all human cancers across the 
world [87] based on known viral containing malignancies such as Burkitt 
Lymphoma (BL), nasopharyngeal carcinoma (NPC), stomach cancer, and diffuse 
large B cell lymphoma (DLBCL). EBV containing tumors have been associated 
with distinct patterns of tumor mutations supporting the role of EBV as an 
oncogenic driver [8,88]. Following primary infection in an immune competent 
individual, EBV is controlled and becomes a lifelong chronic infection. It lies 
latent inside a small percentage (1-10 cells per million) of host B cells, as well as 
possibly a subset of epithelial cells, with minimal protein translation, thereby 
escaping immune surveillance by the human host (reviewed in [4]). EBV 
persistence is associated with a variety of host immune evasion strategies, 
including inhibition of immune cell function, dampening of apoptotic pathways, 
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and interfering with antigen processing pathways. Moreover, since the virus has 
a life-long persistence in 95% of the human population low levels of detectable 
virus do not necessarily imply infected tumor cells but may simply represent 
reactivation of the chronic infection [18].   
 Additionally, it has been shown that activation induced cytidine deaminase 
(AID) is over expressed in EBV positive naive B cells. AID expression in turn 
leads to somatic hypermutations in pro-oncogenic genes such as P53 and BCL6 
which increases the likelihood of of B cell transformation and lymphomagenesis 
[89]. Through this interplay between B cell activation and host immune evasion, 
EBV has the potential to directly influence prognosis or serve indirectly as a 
surrogate of immune competence. An examples of such interplay is inflammatory 
effects of EBV on gastric cancers through pro-inflammatory molecule expression 
such as cytokines (IL6,IL5) [90]. Hence, EBV infection has been associated with 
variety of host gene deregulations and polymorphisms on the host genome.  
Unlike viral messenger RNAs (mRNA), EBV microRNA (miRNAs) are 
ubiquitously expressed during EBV latency and often make up a notable number 
of cellular miRNAs. Viral miRNAs comprise up to 24% of all miRNAs in the B cell 
line, Jijoye [44]. These miRNAs are likely a major way in which the virus 
manipulates the host cells during latency [63]. Studies have suggested that  EBV 
miRNAs are able to dampen immune surveillance of the infected host cells by 
down-regulating important genes in viral detection JAK/STAT pathway [91]. 
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Moreover, EBV miRNAs and EBERs in few cancers have been linked to 
increased aggressiveness and angiogenesis of tumor cells [39,92,93].  
Transcriptome studies have been used to further understand the role of 
EBV in tumorigenesis, but were mainly limited to studying classic cases of EBV-
associated malignancies, such as BL and NPC [8,40]. While EBV has been 
observed in other tumors such as head and neck, lung, ovarian, colon, and 
esophageal cancer, cancers are not routinely screened for EBV. More 
comprehensive analyses are thus limited due to lack of data [94]. One example 
reports a negative effect of EBV with poor prognosis for gastric cancer patients 
with detectable EBV miRNA, miR-Bart20-5p. EBV was also reported to be an 
independent prognostic indicator for patients diagnosed with advanced NPC 
[59,92]. A recent study on 13 cancer subtypes showed the presence of any EBV 
miRNAs putatively increased the aggressiveness of the malignancy but this study 
solely looked for the presence or absence of miRNAs [93].  
Here, we aimed to systematically ascertain and quantify the presence of 
EBV within and across different cancer types by screening for viral miRNA. We 
next developed a computational framework for EBV miRNA detection and 
quantification using publically available data. We categorized viral miRNA 
expression levels as a means to identify EBV-infected tumors and as a covariate 
in survival analyses. 
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III.4 Results: 
III.4.1 Survival Outcome for EBV Positive Tumor Samples Across Cancer 
Subtypes 
Through our pipeline for viral miRNA detection ( Figure 3.1), previously 
described in Chapter 2, after identifying the EBV positive samples, we addressed 
our central question regarding whether EBV impacts the clinical outcome of 
cancer patients, we used our more sensitive measure of total EBV miRNA and 
EBERs in our survival analysis. We therefore examined patient survival across 
tumor types hypothesizing that levels above a normally controlled infection could 
be associated with clinical outcomes. Using both the Kaplan-Meier test and 
general linear model (GLM), we tested EBV positivity, defined by combining high 
and medium levels, as ≥10 CPM in comparison to negative tumors, defined as to 
low or absent expression (<10 CPM). Based on this categorization, only one 
tumor type, adults with acute myeloid leukemia (AML) demonstrated significantly 
different 1000 day survival rates when controlling for multiple testing. EBV 
positive adult AML patients had significantly worse survival rates relative to their 
EBV negative counterparts at 1000 days (P=0.00013 Kaplan Meier, Bonferroni-
corrected P=0.02, Figure 3.2 A, Table 3.1). For EBV positive patients survival for 
an adult AML diagnosis was only 6% (1 out of 15 EBV positive tumors) compared 
to 43% (31 out of 72) for patients with EBV negative tumors, with a odds ratio of 
0.095 (0.012 -0.76). This survival difference was robust even with a lower 
threshold. Moreover, patients who died had significantly higher EBV miRNA 
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levels than those who survived (Figure 3.2B).  Interestingly, this association was 
not observed for pediatric AML where no difference was observed between EBV 
status and survival (56% for EBV positive (n=9/16) and 59% for EBV negative 
(n= 148/247), Kaplan Meier P=0.74). The survival disadvantage in adults was 
robust even after controlling for sex and age (GLM P= 0.0439). EBV infection 
status alone was not significantly associated with other clinical and molecular risk 
factors, including AML French, American and British classification (FAB), based 
on univariate analysis using the 84 of 103 AML samples with detailed clinical 
annotation (Table 3.2). Together, our findings suggested that EBV miRNA levels 
might represent an independent biomarker associated with poor prognosis in 
adult AML.  
III.4.2 Prognostic Risk Model for adult AML Incorporating EBV  
We examined  the potential prognostic power of EBV status for survival in 
conjunction with other known risk factor. We next performed multivariate Cox 
regression analysis across all adult AML tumors between EBV positive versus 
EBV negative samples ( EBV positive ≥ 10 counts per million (CPM) and EBV 
negative ≤ 10 CPM). Our multivariate analysis detected other previously 
associated factors including age, eosinophil levels, inversion 16 and trisomy 21 in 
the tumor that imparted the greatest risk among the  clinical and molecular 
features. We also examined interactions between other measures such as age 
and percent eosinophils, to detect potential confounding hinder prediction. The 
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results indicated <1% confounding suggesting that EBV status is independently 
associated with survival in adult AML (P=0.0045) (Table 3.3). 
 We next tested the prognostic power using a Cox model incorporating the 
above variables and previous risk factors along with EBV status. We again 
examined interactions and removed any highly correlated factors [95] (Figure 
3.3A)). A machine learning algorithm was used to determine the significance of 
the addition of EBV positivity in the prognosis of AML patients. Using 
bootstrapping and cross validation we then tested the prognostic power on 
withheld samples from our Cox-model of survival incorporating EBV status as 
well as other significant univariate predictors (percent eosinophils within tumors, 
Trisomy 21, Inversion 16, and Age). The discriminatory power represented by the 
area under the curve (AUC) improved with the inclusion of  EBV (0.62 to 0.72 
respectively) (Figure 3.3B)). To better assess the significance we permuted EBV 
status which showed that our observation of the AUC was significant (P-
value=0.02). As an alternative model, akin to previous post remission treatment 
(PRT) [96], we used the cytogenetic classification instead of the individual key 
cytogenetic aberrations. Although we were not able to exactly replicate the 
previous PRT score with available data, lacking a measure of blast numbers 
within the TCGA dataset, we again saw EBV status incorporation improve the 
model status (AUC 0.59 to 0.7 for poor and 0.59 to 0.69 for intermediate) 
populations (Figure 3.4, Table 3.4). Overall this suggests that EBV may have 
significant power as as a potential prognostic biomarker for adult AML. 
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III.4.3 Transcriptome Expression Difference Between EBV Positive and 
Negative Adult AML Tumors  
 We next sought to examine potential biological differences that might 
underlie increased levels of EBV miRNA at diagnosis and help explain the 
association with decreased survival. We first performed differential transcriptome 
expression analysis on mRNA expression in relation to EBV status (13 samples 
at CPM≥10, and 14 samples at CPM=0, respectively) with available RNA-seq. 
We detected 18 genes (q≤10%) after we removed genes that were also 
significantly differentially expressed when survivors and nonsurvivors were 
compared in EBV negative cases (Figure 3.5)). Genes previously known to be 
upregulated during EBV infection of B cells were also upregulated in our dataset 
such as HLA-DQ and HLA-DRB [97]. A collection of genes associated with 
inflammation, interferon I and II activity in addition to neutrophil and macrophage 
deregulators were also differentially expressed between EBV positive and 
negative samples. These genes include MX1, ANAX2P2, DEFA1,NCF1C, CLC, 
and SPIB [98–102]. Go biological enrichment analysis showed an increase in 
reactive oxygen species metabolic cell process enrichment when the samples 
were EBV positive (ROS metabolic process). The latter process has been well 
studied in terms of its association with inflammation and increase in cancer cells 
[103]. The genes involved in this process were HBG1, HBG2 and NCF1C. Go 
cellular component enrichment shows higher than average expected of MHC 
Class II proteins (HLA-DR and HLA-DQ) complex involvement in addition to 
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cytoplasmic vesicle formation(HLA-DR, HLA-DQ, DEFA1, VWF,CD163, CRHBP, 
ANAX2P2, LAPTM4B,HBG1 and CRHBP) Reactome pathway analysis showed 
enrichment in immune system signaling such as interferon signaling, alpha 
defensins and cytokine signaling (FDR corrected P value ≤0.05, Table 3.6). 
No viral mRNAs were observed to be relatively enriched, which was not 
unexpected given the normally low expression level of EBV poly A transcripts 
and the reduced or silenced viral gene expression during latency. In fact, we 
could barely detect  viral mRNA reads (<7 RPM per gene) in 13 out of 15 EBV 
miRNA positive AML samples with the greatest combined viral mRNA expression 
of 14.4 reads per million (RPM)(Figure 3.6). The viral genes most evident were 
A73/RPMS1 and EBNA1, consistent with a latency I pattern of infection while 
EBV lytic genes including BALF4 and BNLF2A were sometimes expressed. Two 
AML samples’ mRNA expression was constrained to two latency III genes such 
EBNA-2 and EBNA-LP although we could detect a mix population of lytic genes 
in the rest of the AML samples. The latter finding is consistent with our miRNA 
data which implies viral detection by the host immune system and upregulation of 
the host defense mechanisms due to episodic lytic reactivation. 
III.4.4 Somatic And Germline Variation Landscape Related to EBV Status 
Host genetic variation may also impact the differences between AML 
positive and negative cases. This could be due to somatic variants in the tumor 
as well as the patient’s inherited germline variation. Given our limited sample size 
precluding the power for whole genome analyses, we focused on previously 
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defined somatically mutated genes and germline variants associated with EBV  
Effects of somatic variants have been observed in EBV-associated cancers, 
including NPC and BL where viral presence alleviates/abrogates the need for 
specific particular driver variants [8,88]. Previous associations have been made 
with germline variants and viral control [8,104,105]. To explore the potential role 
of variation, we called variants and germline single nucleotide polymorphysims 
(SNP) variations comparing the 13 positive and 14 negative samples with 
available RNA-seq data. Given the relatively small sample size, we only sought 
to associate variants to known somatically mutated genes or common SNPs. 
Thus, after standard variant calling from mRNA-seq data we filter somatic 
variation to the genes of interest and to known SNPs that were common (5% 
frequency). We were able to identify 28 somatic variants in adult AML. Overall, 
these variants were not associated with EBV or survival outcome as predicted in 
our model ( P-value ≤ 0.05) (Figure 3.7).   
 Given our limited numbers, we examined common inherited variation 
looking at common SNPs (>5% frequency) within our transcripts identifying 
17,891. Hereafter, filtering out the intergenic, splice site and intronic only 4,885, 
remained. The latter variants were examined for previously known or novel snps 
on EBV associated genes. The results identified association for EBV positive 
status on one variant HLA-DRA (rs7195) (Chi-square P =0.03991) on the 3’ UTR 
(Methods). This variant has been first reported in EBV positive patients in a heart 
study and has been found in other EBV cancer patients with EBV positive status 
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[106,107]. Furthermore, we could observe a variant on a previously associated 
gene FCGR2A (rs1801274), which although not reaching significant but seemed 
promising. The heterozygous variant was observed in 5 EBV positive samples 
and no EBV negative adult AML samples however we did not have enough 
power for association (Chi-square P=0.07956) [107]. 
III.5 Discussion 
Ninety five percent of the world's population is asymptomatically infected 
with EBV yet it is not fully understood why certain individuals develop EBV 
cancers that manifest high levels of this herpesvirus in their tumors [87]. Through 
our EBV detection bioinformatics pipeline (utilizing miRNA seq) across cancers, 
we surprisingly found a novel association with viral levels and poor survival in 
adult AML patients.  
Given our novel association with adult AML survival, we focused on further 
exploring its potential as a prognostic marker as well as its biology. From 
univariate analysis, it did not appear to be associated with a particular type of 
AML nor with known previous factors associated with survival. Using Cox 
modeling EBV status appears to be an independent biomarker for survival and 
improves predictions when incorporated into a risk model along with other 
factors. This was also supported within previous risk models (PRT). While this 
association requires additional validation in an independent cohort, it will be 
interesting to determine whether other measures of EBV, such as peripheral viral 
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loads or peripheral miRNAs, may act as surrogates and or provide longitudinal 
information during treatment and remission.  
To explore the biology of this association, examined expression 
differences between the tails of viral expression: samples with medium levels 
compared to those with no evidence of viral miRNAs. We also carefully controlled 
for associations that may be simply related to death by removing those 
differentially expressed genes associated simply with more outcome no matter 
the viral expression. What we observed was a set of genes that appeared 
enriched in EBV positive patients. Expression differences correlating with innate 
inflammation. While this is difficult to perfectly control, given AML represents an 
innate precursor, one of the most interesting genes showing expression 
differences was MX1 has been linked not only to EBV but progression of acute 
leukemia by acting as a binding partner of LMP1 viral gene in EBV positive 
samples in acute lymphocytic leukemia but as tumor inducing factor in myeloid 
leukemia. MX1 is involved in Interferon alpha and gamma has been associated 
with reactivation of EBV infection in gastric cancer and lymphomas [108].  
We further investigated the effects of possible EBV polymorphism 
landscapes on the host. We observed the previously EBV associated SNP on 
HLA-DRA (rs7195) significantly found on EBV positive samples in comparison to 
EBV negative samples. We further found a potentially significant variant FCGR1 
(rs11810143) but due to lack of power could not confirm as EBV associated. The 
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latter is important, as these variants can be used as markers for susceptibility or 
protection against EBV in adult AML patient. 
Taken together, we would propose a model that EBV levels in adult AML 
predominantly reflect the immune status of the patient, with higher EBV levels for 
the most part reflecting immune frailty represented by poor EBV control. EBV is 
easily perturbed and reactivated by immune insults. This frailty could be general 
or may be specific to the local tumor microenvironment. Further exploration 
examining EBV from peripheral blood as well as tumor could help answer such 
questions. The idea that this represents an immune deficiency arising in adults is 
supported by our lack of association in pediatric AML who are less likely to have 
become EBV infected. Our lack of association in pediatric AML may be due in 
part to the relative lack of children being infected with EBV compared to adults. 
All together, our data suggest a possible non-adapted immune response, 
leading to a high inflammation disease which is associated with poor prognostic 
[109]. The latter deregulations could lead to lower survival of these patients 
Figure 3.8. 
Based on our data, many cancers show presence of EBV miRNAs and as 
the virus has been associated with manifestation and progression of many 
cancers, it is very important to understand the pan cancer affects of the virus on 
human host. Moreover, EBV miRNA levels could be used to risk stratify cancer 
patients to undergo antiviral or immunotherapy in adult AML patients. 
Furthermore, our implemented machine learning algorithm can be adapted to 
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evaluate clinical data while measuring the effects of EBV and other risk factors 
as a risk to patient survival retaining diagnostic value in our case for AML 
patients. This method can potentially be utilized for other clinical studies with low 
sample size. Our findings highlight the importance of personalized 
immunotherapy in regard to the status of the the patient immune system and 
tumor-derived signals.  
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III.6 Materials and Methods: 
III.6.1 Survival Analysis 
Survival analyses were performed in R including Kaplan-Meier survival 
analysis (using survival package), as well as univariate and multivariate logistic 
regression. Exclusion of potential confounders was determined by measuring the 
association before and after adjusting for potential confounding variable and 
subsequently excluding variables with greater than 10% change of effect [110]. 
III.6.2 Hazard Analysis Using Cox Regression With Bootstrapping And 
Cross Validation  
In order to assess the risk associated with the hazard of EBV positivity in 
our dataset, we used the standard Cox multivariable risk assessment method to 
regress the parameters of interest jointly. The R scripts for Cox-regression, 
bootstrapping and risk prediction using cross validation is available through 
GitHub (https://github.com/bailey-lab/EBV_Cox-Regression.git) utilizing the 
censboot and Cox-regression packages using the general multivariate estimator 
g(x,ß)= exß in R. To test prognostic power, we used a multivariate 1000 
bootstrapped leave one out cross validated model to predict the risk associated 
with being EBV positive in concordance with patient survival, whereby we 
estimated the risk of EBV positivity of our parameters [111,112]. Area under the 
curve (AUC) for the performance of our prediction model was estimated at 
various thresholds to ascertain the risk of the strata (EBV) factor for every 
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predicted sample and permutation was used to determine the significance of 
AUC curves. 
III.6.3 Differential Expression Analysis 
Differential expression analysis comparing EBV positive versus EBV 
negative samples was performed using the Tuxedo Tools. Gene ontology (GO) 
enrichment and pathway analysis was done using python in house scripts 
utilizing Panther and GREAT database plus reactome [113,135]. The predicted 
GO terms and pathways were selected only if the FDR for enrichement 
concidering background genes was >0.1 predicted by the databases. 
III.6.4 Human Variation Detection and Association 
To investigate human germline SNP variation and somatic variants were 
called from the mRNA-seq data as previously described using TopHat 
(Version/2.1.1) [114–116]. Briefly, this variant calling  pipeline was implemented 
using SAMtools [84]  and VCFtools (version/0.1.11) [86]. Variants were filtered to 
minimize false positive calls requiring a minimum base quality (phred score) 20, a 
minimum mapping quality of 20, and a minimum of 10 supporting reads for a 
variant. SeattleSeq (version 137) was used to functionally annotate variants[117].  
Given the limited number of samples, we focused on common variants and 
partitioned variants as likely germline inherited variation and as likely somatic 
variation. First, somatic variants were focused on known AML mutated genes 
and defined as those that did not exist in dbSNP ( build 151). Germline variants 
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at  dbSNP  with a minor allele frequency (MAF) >0.5 in dbSNP were assessed 
[118]. Germline SNPs were excluded if identified intronic, intergenic and 3’ and 5’ 
splice site variants as a conservative filter in order to avoid false positives due to 
improper alignment at edges of exons. These SNPs were then filtered based on 
the previously assciated SNPs with EBV or the genes which the latter were 
observed in. Chi-square test was performed for the latter snps in relation to EBV 
status suing in house R script.     
III.6.5 Data Visualization 
Data visualization was done using a variety of standard tools including libraries 
ggplot2, qqman, prcomp, dplyr and pheatmap were used to make the figures. All 
statistical analysis was done using validated R, and python functions. 
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III.7 Figures 
 
Figure 3. 1. Overall pipeline for EBV identification and our downstream 
analysis. 
miRNA seq data was downloaded from TCGA, TARGET or our own cohort of 
eBL samples. The files were reverted to fastq, and aligned to a concatenated 
human and EBV genome to insure the best alignment match and limiting multi-
mapping reads. The viral non-coding RNA loci was assigned to the mapped 
reads and counts per million of the viral reads to the total library was estimated. 
Hereafter, statistical clinical associated followed by machine learning was utilized 
to understand survival association. Additionally, the detected EBV positive 
samples in comparison to those with no viral reads detected were further 
examined for mRNA level differences and miRNA variations across samples. 
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Figure 3. 2. Survival analysis and prognostic model for EBV status in adult 
AML. 
 A. Kaplan-Meier curve compared the survival of EBV positive (blue) versus 
negative (red) AML patients in 1000 day survival analysis which significantly 
differed (P<0.00013). B. The difference in total miRNA EBV levels was 
remarkable when comparing patients who survived or died with only one survivor 
greater than 101 CPM (wilcoxon rank test P-value =9.3x10-07)  
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Figure 3. 3. Cox regression model. 
A. 2 Spearman correlation of various clinical factors including EBV and the 
number of viral sncRNA reads. B. Area under the curve (AUC) based on cutoffs 
for the multivariate Cox prediction model using bootstrapped cross validation 
when EBV was modeled as a feature along with age, percent eosinophils, and 
number Trisomy 21 inversion 16 mutations. 
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Figure 3. 4. Cox regression on cytogenetic classification of Adult AML.   
A. Multivariate cox – regression model with cytogenetic outcome factors as the 
co-variants. B & C. AUC curves for the model if cytogenetic factors were used as 
the main strata with and without EBV present in the model. 
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Figure 3. 5. Differential mRNA transcriptome gene expression analysis 
comparing AML cases with medium and no  EBV miRNA expression.  
Volcano plot showed differential expression between samples above 10 CPMs of 
EBV reads (n=13) and those lacking viral miRNA and EBER expression (and 
n=14). Genes which were colored orange posses q-values (false discovery rate) 
below 0.1. 
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Figure 3. 6. Viral mRNA expression in adult AML patients. 
 EBV mRNA reads per kilobase of transcipts per million (RPKM) across EBV 
positive adult AML patients. Viral mRNA expression of 13 EBV positive samples 
based on RNA seq analysis. Grey represent viral mRNAs not expressed in the 
samples. 
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Figure 3. 7. Polymorphism in EBV positive compared to negative adult AML 
samples.  
A. Heatmap representing correlation between EBV positive status and known 
mutations across AML mRNA cohort in our study. Side bar plots show the 
percent mutations across EBV positive versus EBV negative samples (P>0.05 
chi-square test for all genes in correlation to EBV status of patients) (n=27 EBV 
positive n=13 and negative n=14 tumors). B. Bar plot showing average number 
of snps per tumor for known AML genes in EBV positive and EBV negative 
samples. (P-Value = 0.8742). 
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Figure 3. 8. Proposed Model Span of Alteration in Host Expression in EBV 
Positive AML Samples 
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III.8 Tables 
Cancer 
EBV 
Positive 
Samples 
(10 CPM 
threshold) 
EBV 
Negative 
Samples 
(10 CPM 
threshold) 
P - value 
(Kaplan-
Meier) 10 
CPM 
threshold 
Type of 
EBV 
Positive 
Association 
with 
survival 
P - value 
(Kaplan-
Meier) 5 
CPM 
threshold 
P-value GLM* 
Adrenal Gland Cancer 1 94 NA NA NA 0.996 
Adult AML 13 87 0.00013 Negative 0.051 0.044 
Bladder Carcinoma 44 408 0.049 Positive 0.063 0.056 
Brain Cancer 9 482 0.094 Positive 0.061 0.975 
Breast Cancer 10 438 0.75 Negative 0.81 0.891 
Cervical Cancer 15 175 0.45 Positive 0.49 0.370 
Colon Adenocarcinoma 91 352 0.90 Negative 0.96 0.184 
Diffuse Large B Cell Lymphoma 15 30 0.87 Negative 0.95 0.243 
Endemic Burkitt Lymphoma 17 2 NA NA NA 0.997 
Esophageal Cancer 52 133 0.021 Negative 0.08 0.075 
Head and Neck Cancer 71 453 0.072 Positive 0.091 0.058 
Kidney Papillary Cell 
Carcinoma 2 163 0.6 Positive 0.72 0.990 
Kidney Renal Clear Cell 
Carcinoma 5 479 0.97 Negative 0.99 0.494 
Liver Carcinoma 10 361 0.23 Negative 0.30 0.622 
Lung Adenocarcinoma 35 459 0.051 Positive 0.06 0.256 
Lung Squamous Carcinoma 15 101 0.40 Positive 0.70 0.288 
Ovarian Cancer 11 473 0.95 Negative 0.98 0.627 
Pediatric AML 16 247 0.74 Negative 0.85 0.595 
Prostate Cancer 2 478 NA NA NA 0.993 
Rectal Adenocarcinoma 41 120 0.59 Positive 0.46 0.107 
Sarcoma NA NA NA NA NA 0.988 
Stomach Adenocarcinoma 539 97 0.30 Negative 0.35 0.621 
Testicular Cancer 4 130 0.72 Positive 0.64 0.996 
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Thymoma 2 122 NA NA NA 0.993 
Thyroid Cancer 2 130 NA NA NA 0.995 
Uterus Cancer 16 531 0.74 Negative 0.85 0.322 
Wilms Tumor 0 139 NA NA NA 1.000 
 
Table 3. 1.Kaplan Meier analysis across cancer for EBV-associated 
survival. 
P-values are uncorrected; Orange signifies Significant P value with after multiple 
test correction (Bonferroni test), P=0.02.Purple signifies cancer which had P 
values below 0.05 but were not significant after Bonferroni test.NA is for cancer 
lacking survival status and/or survival time as well as samples without <=2 EBV 
positive samples.GLM model was run on 1000 day survival or reported 
categorical survival status if this was lacking. 
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Total n of 
Pos EBV 
n of Pos 
Condition 
in EBV 
Positive 
n of Neg 
Condition 
in EBV 
Positive 
Total n 
of Neg 
EBV 
n of Pos 
Condition 
in EBV 
Negative 
n of Neg 
Condition 
in EBV 
Negative 
Fisher's 
Exact test 
Wilcoxon 
rank test 
Inversion 16 15 2 13 77 5 72 0.345 NA 
idh1_r140 15 1 14 76 5 71 1.000 NA 
idh1_r132 15 0 15 76 8 68 0.344 NA 
del(5q)/5d- 15 1 14 77 6 71 1.000 NA 
del(7q)/7d- 15 2 13 77 8 69 1.000 NA 
Inversion 8 15 1 14 77 8 69 1.000 NA 
NPMc 15 3 12 77 18 59 0.754 NA 
Translocation 4-11 15 1 0 91 14 77 0.461 NA 
Translocation 15-
17 15 1 14 77 6 71 1.000 NA 
Translocation 9-11 15 0 15 77 1 76 1.000 NA 
Trisomy 21 15 1 14 77 3 74 0.524 NA 
FLT3 15 3 14 73 18 56 0.753 NA 
Gender 15 7 8 77 31 46 0.807 NA 
M0 Stage 15 0 15 77 10 67 0.351 NA 
M1 Stage 15 4 11 77 16 61 0.744 NA 
M2 Stage 15 1 14 77 20 57 0.298 NA 
M3 Stage 15 1 14 77 7 70 1.000 NA 
M4 Stage 15 6 9 77 16 61 0.235 NA 
M5 Stage 15 1 14 77 7 70 1.000 NA 
M6 Stage 1 1 0 87 14 73 0.271 NA 
M7 Stage 15 1 14 77 1 76 0.459 NA 
% Lymphocytes 15 NA NA 77 NA NA NA 0.824 
% Monocytes 15 NA NA 77 NA NA NA 0.605 
% Eosinophil 15 NA NA 77 NA NA NA 0.974 
% Neutrophil 15 NA NA 77 NA NA NA 0.560 
% Myelocyte 15 NA NA 77 NA NA NA 0.903 
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Table 3. 2.Univeriable Association test for EBV negative versus positive 
AML samples.  
M represent the the subtype of AML based on French -American-british (FAB) 
categorization (M0-M6). Each translocation is from a chromosome to another, for 
example Translocation 8-21 is a translocation from chromosome 8 to 
chromosome 11. The cytogenetic deletion on various sites and sizes on 
chromosome 7, and 5 are represented by del. Mutations on the IDH1  gene on 
arginine amino acid (r) on various sites (132,140) observed in adult AML tumors. 
FLT3 mutation are consistently observed in forms of insertion, deletions and 
missense and intronic variants and reported as part of patient clinical information. 
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Feature Coefficient Pr(>|z|) 
Age 2.22E-02 0.08207 
EBV 1.32E+00 0.0045 
Eosinophil Percent 2.52E-01 0.00457 
Lymphocyte Percent 3.86E-05 0.99648 
Myelocyte Percent 3.96E-02 0.55609 
Neutrophil Percent -6.65E-03 0.62223 
Monocyte Percent 2.09E-03 0.95954 
Translocation 8-21 -3.28E-01 0.64948 
Inversion 16 -2.34E+00 0.03145 
Translocation 8 9.62E-02 0.87208 
del(5q)/5d- 1.01E+00 0.12995 
del(7q)/7d- 7.36E-01 0.25181 
Translocation 9-22 -1.38E+01 0.98869 
Trisomy 21 2.75E+00 0.00411 
Translocation 4-11 -2.02E+00 0.14934 
Translocation 9-11 1.89E+00 0.15012 
Translocation 15-17 -1.39E+00 0.16105 
idh1_r140 1.20E-02 0.98419 
idh1_r132 -2.22E+00 0.0387 
NPMc 4.37E-01 0.37311 
FLT3 -5.90E-02 0.88937 
Gender -4.17E-01 0.30107 
 
Table 3. 3.Multivariable Cox regression for AML samples. 
The coefficient represents the impact of features. Pr(>|z|) defines the statistical 
significance. |z| is the absolute value of the Wald statistics. It represents if the 
feature coefficient is statistically different from zero. Each translocation is from a 
chromosome to another, for example Translocation 8-21 is a translocation from 
chromosome 8 to chromosome 11. The cytogenetic deletion on various sites and 
sizes on chromosome 7, and 5 are represented by del. Mutations on the IDH1  
gene on arginine amino acid (r) on various sites (132,140) observed in adult AML 
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tumors. FLT3 mutation are consistently observed in forms of insertion, deletions 
and missense and intronic variants and reported as part of patient clinical 
information. 
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Variant P Value 
Age 0.00069 
EBV 0.00059 
Gender 0.81 
Eosinophil 0.0023 
Lymphocyte 0.98 
Myelocyte 0.25 
Neutrophils 0.27 
Monocyte 0.27 
Percent_Blast 0.83 
Intermediate 0.034 
Poor 0.053 
Table 3. 4. Cox Regression for Cytogenetic Model With EBV As The Main 
Strata.  
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Gene EBV	Positive	
Average	RPKM 
EBV	Negative	
Average	RPKM P_value Log2FoldChange q	value 
HLA-DQA2 74.05 12.33 0.00005 -2.586 0.03 
CRHBP 20.11 3.95 0.00005 -2.347 0.03 
DEFA1 20.3 0 0.00005 -3.242 0.03 
NCF1C 24.18 5.05 0.00005 -2.259 0.03 
HLA-DRB6 64.98 22.09 0.00005 -1.557 0.03 
LGR6 7.74 0.84 0.00005 -3.199 0.03 
PCSK6 10.25 1.87 0.00005 -2.456 0.03 
HBG1 1512.76 183.71 0.00005 -3.042 0.03 
HBG2 2238.61 178.64 0.00005 -3.647 0.03 
ADAMTS2 1.57 16.86 0.00005 3.421 0.03 
CLC 7.72 42.35 0.00005 2.455 0.03 
CD163 14.34 82.47 0.0001 2.524 0.06 
LAPTM4B 3.47 14.48 0.0001 2.06 0.06 
VWF 1.09 7.27 0.00015 2.734 0.08 
SPIB 8.72 2.28 0.00025 -1.935 0.09 
GOLGA8A 4.09 12.83 0.0003 1.649 0.1 
MX1 39.06 9.03 0.00036 -2.113 0.1 
ANXA2P2 97.83 42.47 0.0004 -1.204 0.1 
 
Table 3. 5. Differentially expressed EBV associated genes independent of 
survival (all genes P<=0.05). 
Reference genes from hg19 Genome Assembly. Log2 Fold Change 
demonstrates change in expression from EBV positive to EBV negative samples 
(negative values EBV+ > EBV-).RPKM = reads per kilobase per million. 
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Reactome Enriched 
Pathway name 
Entities 
found 
Entities 
total P-value FDR Submitted entities found 
Interferon Signaling 6 392 4.10E-05 0.004 MX1;HLA-DRA;HLA-DQA2 
Factors involved in 
megakaryocyte 
development and 
platelet production 
4 194 3.09E-04 0.01 HBG2;HBG1 
Interferon gamma 
signaling 4 250 7.99E-04 0.02 HLA-DRA;HLA-DQA2 
Cytokine Signaling in 
Immune system 7 1055 1.48E-03 0.03 
MX1;HLA-DRA;CLC;HLA-
DQA2 
Translocation of ZAP-70 
to Immunological 
synapse 
2 42 2.36E-03 0.03 HLA-DRA;HLA-DQA2 
Phosphorylation of CD3 
and TCR zeta chains 2 45 2.70E-03 0.03 HLA-DRA;HLA-DQA2 
PD-1 signaling 2 45 2.70E-03 0.03 HLA-DRA;HLA-DQA2 
Generation of second 
messenger molecules 2 58 4.42E-03 0.04 HLA-DRA;HLA-DQA2 
NGF processing 1 5 8.50E-03 0.07 PCSK6 
Expression and 
Processing of 
Neurotrophins 
1 5 8.50E-03 0.07 PCSK6 
Hemostasis 5 830 1.19E-02 0.08 VWF;HBG2;HBG1 
Costimulation by the 
CD28 family 2 97 1.19E-02 0.08 HLA-DRA;HLA-DQA2 
Alpha-defensins 1 11 1.86E-02 0.1 DEFA1 
Downstream TCR 
signaling 2 124 1.89E-02 0.1 HLA-DRA;HLA-DQA2 
GP1b-IX-V activation 
signalling 1 12 2.03E-02 0.1 VWF 
Table 3. 6. Reactome pathway prediction for differentially expressed genes 
in adult AML in correlation with EBV status. 
Entities found: Number of molecule found in the pathway. Entities total: Total 
number of molecule found in the pathway. 
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IV CHAPTER IV: Deciphering molecular differences in EBV positive 
population of stomach cancer through EBV ncRNAs 
IV.1 Preface: 
The methodology and content of this chapter is adapted from a manuscript under 
preparation. The authors of this manuscript are M. Movassagh, C. Forconi, A. 
Moormann, J. Bailey, “Deciphering molecular feature differences in EBV positive 
population of stomach cancer using EBV miRNAs and EBERs.” 
IV.2 Abstract: 
  Epstein Barr virus (EBV) has been well correlated with stomach cancer. In 
fact, an entire category of stomach cancer called EBV-associated gastric cancer 
(EBVaGC) has a different pattern of mRNA expression and pathways involved in 
comparison to other subtypes of gastric cancers. Here, we use miRNA 
sequencing (miRNA-seq) to detect EBV-positive stomach cancers. Furthermore, 
we classify the identified EBVaGC tumor samples into two subgroups of “high” 
and “medium” viral miRNA expression. These two subgroups possess disparate 
behaviour in terms of host mRNA expression and pathways involved. The “high” 
EBV population shows activation of genes involved in host immune dampening 
and genes previously known to be associated with EBV host manipulation. The 
“medium” population shows elevation in host genes related to inflammation, 
neutrophil deregulation, and uncontrolled EBV reactivation. We report no 
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significant survival differences in “high” versus “medium” and “EBV negative” 
subpopulations in our cohorts. Furthermore, through multiple regression 
modeling and association, we deciphered the roles of EBV miRNAs with high 
expression levels (≥1000 copies per million (CPM)) in relevance to host mRNA 
expression in order to determine targets of these non-coding (ncRNAs) and their 
involvement in various pathways they influence in stomach cancer. Based on our 
analysis, EBV miRNAs mainly influence pathways involved in viral persistence 
and dampening the host immune system. 
IV.3 Introduction:  
Involvement of Epstein Barr virus (EBV) in cancer is well established in 
gastric cancer. EBV-associated gastric cancers (EBVaGC) are observed in 
approximately 10-15 % of all cases of stomach adenocarcinomas [13].  Various 
socioeconomic and geographical regions across the world show differing 
frequencies of EBVaGC reportedly ranging from (1.3-30.9%) [13].  
The main method for deciphering EBV status in these patients is through 
either staining for EBV-encoded RNAs (EBERs) or measuring viral mRNA 
expression [56]. EBVaGCs are allegedly in latency I or II in terms of viral life 
cycle. For latency II, it infers the virus has low levels of mRNA expression and 
only a few viral mRNAs such as LMP1, LMP2 and EBNA1 being expressed 
[56,119]. Furthermore, TCGA characterization of EBVaGC was mostly based on 
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expression of EBERs and viral genes with a maximum of 5 RPKM in the 
BAMH1A region [120]. The BAMH1 rightward transcript region is where EBV 
LMP1, and LMP2 transcripts lie [121]. This region is also where EBV Bart 
miRNAs are located [122]. EBV miRNAs are expressed during all latencies of the 
viral life cycle, hence, in cases with viral mRNA expression too low to detect, the 
use of EBV miRNAs can be utilized as a proxy read out for EBVaGCs. 
Additionally, there have been reports of EBV-positive but EBER-negative tumors 
which further emphasizes the use of miRNA sequencing to determine EBV status 
of gastric tumors when possible [57]. 
 There are several ways to categorize gastric cancer; some examples are: 
Anatomical classification (Borrmann classification and Siewert and Stein 
classification), histological classification (world health organization (WHO) 
classification and Lauren’s classification), extent of disease (early gastric cancer 
versus advanced cancer) and The Cancer Genome Atlas (TCGA) stomach 
cancer classification based on gene expression, mutational landscape, and 
methylation status [123]. TCGA sub-categorizations are based on various 
molecular features of stomach cancer tumors: These subcategories are hyper 
mutated (MSI), genomically stable (GC) and chromosomal instability (CIM, with a 
molecular signature of increase in FGFR2 or HER2 or KRAS or EGFR genes) 
and EBV associated subtypes [123]. EBVaGCs have been shown to have better 
prognosis in response to chemotherapy in comparison to other forms of gastric 
cancer. However, the role of the virus in survival of the patients has not been fully 
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investigated [124]. In particular, EBV miRNA presence such as ebv-mir-bart20 
have been implicated with lower survival in gastric cancer patients [92]. Hence, 
understanding the potential contribution in pathogenesis of viral miRNAs is 
important.  
Based on TCGA characterization, the main pathways upregulated or 
deregulated in EBVaGCs focus on maintenance of virus in the host and involve 
the interplay of the host, with increases in tumorigenesis genes or 
downregulation of the tumor suppressor pathways [13]. Some of these elevated 
tumorigenic genes are JAK2, PI3CA, Bcl-2, cyclin D1 and IHH, while the 
downregulated genes are ARID1A, P16, PTEN and SSTR1 [13]. Thus, EBV 
seems to play a major roles in the molecular environment of the EBVaGCs. 
The process of identifying targets of human miRNAs starts with utilizing 
computational tools, which encompass seed matching information and parsing of 
alignment between miRNA and the target while taking into account 3’UTR 
information, folding energy calculation, and evolutionary stability of the miRNA 
seed site while making such estimation [125,126]. Various tools perform the latter 
task and can be adapted to find many targets for EBV miRNAs [125]. Afterwards, 
the targets need to be confirmed by experiment [127]. A combination of statistical 
and computational methods and models have been utilized to determine targets 
of miRNAs in association with mRNA sequencing data [128]. Although the field 
has improved in terms of using different models and algorithms for determining 
candidate targets of miRNA, identifying and narrowing down the list of viral 
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miRNA direct targets remains difficult [55]. A method that could decipher the EBV 
miRNA with the largest effect on its target’s expression would help us unravel the 
mechanism of the viral miRNA involvement in EBVaGCs. 
Here, we use a combination pipeline of available output genes from 
miRanda miRNA target prediction in addition to our multiple linear regression 
model of human and viral mRNAs in correlation with viral miRNA sequencing to 
unravel the association between the 8 highly expressed (average counts per 
million (CPM) ≥1000) viral miRNAs and their targets in EBVaGC[129]. 
 Furthermore, we characterize two EBV positive EBVaGCs subpopulations, 
each of which has a different pattern of human mRNA expression and high to 
medium levels of viral miRNA expression. This is important as various 
categorizations of gastric cancer has had their own challenges in terms of 
molecular signature categorization for optimal survival prognosis and prospective 
treatment choices [123]. Hence, in order to decipher various molecular 
signatures of stomach cancer further categorization is needed in order to improve 
prognostics and therapeutics for this cancer [123]. 
IV. 4 Results: 
IV.4.1 Characterizing Two Population of EBV Positive Stomach Cancers 
EBV positive status was determined based on the level of viral miRNA and 
EBER expression explained in Chapter II (methods). Overall 76% of gastric 
tumors are determined as EBV positive. The EBV positive tumors make up two 
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population (Figure 4.1A). A population with high levels of EBV miRNA and EBER 
expression (≥10,000 CPM) of viral miRNA expression 7.5%(n=34). Interestingly, 
68.5% (n=321) of gastric cancers fall within the medium category (10-10000 
CPM). Based on Principal component analysis (PCA), the latter population 
appears to be distinct from the samples with the high population in terms of 
miRNA and EBERs abundances (Figure 4.1B). 
We next deciphered potential differences between these two population by 
performing hierarchical clustering on the EBV miRNAs and EBERs of these two 
groups (Figure 4.1C). We did not observe differences in terms of particular 
miRNAs or EBERs being expressed in one population in comparison to another, 
however we saw an overall decrease in the levels of viral miRNAs in the medium 
versus high group. Interestingly, the difference between these two groups could 
not be explained by expression of EBERs, consistent with the new literature on 
EBERs [57]. We observed presence of EBER positive tumors in medium group 
as well as the high group, and concordantly, the levels of expression seemed to 
be the main reason for separation of these groups. The latter not only confirmed 
EBV positive samples do not always show EBERs expression, but that viral 
miRNAs, when available, might prove as better predictors of EBV positive status 
of stomach cancer tumors than mRNA levels.  
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IV.4.2 Specific Transcriptome Signatures Between The Two Groups of EBV 
Positive Stomach Cancers 
 We utilized matching RNA-seq data for the miRNA sequence in order to 
explain (if any) gene expression differences between the medium and high 
EBVaGC subgroups (n matching high miRNA and mRNA sequencing data = 16 , 
n matching medium miRNA and mRNA sequencing = 85 characterized). Using 
these datasets we aimed to comprehend the differences in differential mRNA 
expression between the high versus medium group, high versus EBV negative 
group and medium versus EBV negative groups. Differential expression reported 
differences in the host mRNA signature of these stomach cancer patients. First, 
we looked at possible signatures for the EBV positive high stomach cancer group 
versus the medium group. Signature differences between the populations based 
on reactome predictions showed clear IL10 signaling and wnt signal transduction 
pathway overrepresented in EBV positive high group in comparison to the 
medium and low group (characterized as EBV negative group based on our 
categorization) (Figure 4.2A, 4.2B, Table 4.1, 4.2 , 4.3). We next observed 
through reactome pathway analysis and GO enrichment an increase in the 
defensin pathways (DEFA6, DEFA5, PRSS1, PRSS2, PRSS3), neutrophil 
deregulation and, importantly, FGFR2 pathways enrichment in the medium group 
comparison to high group (Figure 4.2C Table 4.4). Finally, the low/EBV negative 
group showed a particular MTF1 gene activation. Notably this population showed 
higher FGFR2 expression than the high population but no significant change of 
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this gene was observed in the medium ( high versus low FGFR2 q=0.0111602). 
This suggests the presence of a different signature between the gene expression 
in the EBV positive medium and high EBV groups. Additionally, the high 
expression of FGFR2 suggestes the medium EBV positive groups were part of 
the previously categorized CIM populated characterized by marked 
overexpression of this gene.  
We further investigated the changes in the EBV mRNA levels in order to 
understand possible gene patterns of expression of the virus (Figure 4.3A, 4.3B). 
We could identify 10 tumor samples from the 34 samples with more than 4 
unique transcripts expressed EBV genes across the high population and 27 out 
of 85 samples with above 4 transcripts being expressed in the medium 
population. We could identify all but one of the samples as EBER positive in the 
high EBV population and 9 samples in medium population were also EBER 
positive. The viral mRNA gene expression also showed high expression of 
LMP2a, and LMP2b genes in addition to LMP1 genes which are signatures of 
latency II and latency I EBV infection in the high group in agreement with the 
literature [56]. We further concluded that, based on our analysis, not all EBV 
positive tumors are EBER positive and that EBER positive tumors can belong to 
the high or medium categories of EBVaGC.  
IV.4.3 EBV Associated Survival Analysis of Stomach Cancers 
In order to characterize survival differences and see the potential 
prognostic effects of EBV between the two high and medium subpopulations of 
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stomach cancer and EBV negative samples, kaplan meier survival analysis was 
performed(Figure 4.4A to G). Consistent with previous studies we observed no 
survival disadvantage with EBVaGCs groups and long term survival in the rest of 
the subgroups [130]. However, we did observe a potentially significant short term 
lower survival (90 days survival) between our high EBVaGC group versus the 
EBV negative groups (p=0.041, q=0.127)(Figure 4.4.E,F,G). Although we could 
not observe significance between these groups after bonferroni correction, it 
could be further investigated in a larger sample set. Within EBVaGC, there were 
no survival differences observed between high versus medium subgroups, and 
neither were any differences observed between the EBVaGC subgroup and 
low/EBV negative subgroup.                                                       
IV.4.4 EBV miRNA Target Detection in Stomach Cancer High Population 
 The roles of EBV miRNAs has not been extensively investigated in terms 
of their exact targets and how they might potentially regulate the cancer 
microenvironment. Here, we designed a framework of pipelines and statistical 
methods to conservatively detect the targets of these EBV miRNAs. Our 
multivariate regression model was designed in order to calculate the association 
between the miRNAs with above  an average of 1000 CPM in our high population 
and the mRNA level of these individuals ( both in the matching host and the virus 
transcriptome). Furthermore, we take into account the miRanda target scores of 
viral miRNAs when assessing if these genes are truly the targets of these 
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miRNAs (detail in methods section). We applied our model on the data on 
several various combination:  
First, we looked at the individual miRNA (n=8, mir-bart8-3p, mir-bart11-3p, 
mir-bart22, mirb-bart6-3p, mir-bart-7-3p, mir-bart10,mir-bart9 and mir-bart17-3p). 
We observed levels of mRNA of 11 targets significantly inversely associated with 
2 viral miRNAs, ebv-mir-bart8-3p and ebv-mir-bart22 (P ≤0.05, FDR≤0.1) (panel 
of Figure 4.5, Table 3A). Reactome pathway enrichment of these targets 
reported enrichment in pathways involved golgi trafficking, endocytosis and 
envelope formation, the latter signifies viral miRNA involvement in altering the 
lytic viral phase to latent phase (Table 4.6). We also looked at how these viral 
miRNAs could affect the mRNA expression of the virus and observed an inverse 
correlation between 3 viral miRNAs and in the 5 viral mRNAs (mir-bart22, mir-
bart17-3p,mir-bart6-3p) (P ≤0.05, FDR≤0.1) (Table 4.7). Individual literature 
search for these viral genes identified these genes as viral genes involved in the 
lytic phase. Hence, based on the results of this model, 5 targets of these 3 
miRNAs which seem to be also involved in the change of the virus lytic phase to 
latency. The latter is in concordance with the EBV mRNA pattern of expression 
discussed before in addition to previous literature associated with the overall in 
vitro studies of some of the targets of these miRNAs [66]. 
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Next, we adapted our model to investigate the effects when adding all 8 
miRNAs on the host and viral mRNA genome in a multivariable model. We 
observed an inverse correlation with 16 targets on the human transcriptome (P 
≤0.05, FDR≤0.1) (Table 4.8). Based on reactome pathway enrichment these 
miRNAs targeted mainly the host immune system (defensins pathway targeting) 
by regulating the viral traffic and endo/exocytosis across the host membrane 
(Table 4.9). As expected, when looking at the effects of these viral miRNAs on 
the the virus genome, we observe an inverse correlation between the viral 
miRNAs and the mRNAs. We found 2 new lytic gene targets (BXLF1 and BZLF1) 
and 2 viral mRNAs (BALF5 and BRLF1) which were predicted as targets in our 
previous model as well (Table 4.10). 
Finally, We decided to alter our model to observe the synergy between 
these miRNAs on their targets. We tested our hypothesis on the viral miRNAs 
which previously showed the most significant association with their targets. First, 
we checked for the  synergistic effects of ebv-mir-bart8-3p and ebv-mir-bart22 
with either each other or the other 6 highly expressed viral miRNAs on the 
human or viral transcriptome. We observed synergistic relationship between 2 
pairs of miRNAs: first ebv-mir-bart8-3p and ebv-mir-bart10 pair and next ebv-mir-
bart22 and ebv-mir-bart10 pair (Table 4.11). These targets were mainly involved 
in innate immunity. Finally, we looked at the synergistic effects of other viral 
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miRNAs. We found 11 various targets affected by synergistic effects of ebv-mir-
bart22 and 3 different miRNAs (ebv-mir-bart10, ebv-mir-bart9 and ebv-mir-bart6-
3p, P≤0.05, FDR≤0.1). The latter EBV genes were all involved in the lytic phase 
of virus (Table 4.12). 
As an overall prediction result, we performed FDR correction (P≤0.05, 
FDR≤0.1) on the results of all three approaches to identify the significant targets 
identified across all models. We found 7 different targets from 6 different 
miRNAs. 5 of these targets were human genes (TNFIP6, LOC96610,SPP1,CRP 
and FKB10) and 2 were viral genes (BALF5 and BZLF1) (Table 4.13).  4 of these 
targets were results of synergetic viral miRNA targeting and the rest were results 
from individual EBV miRNA targeting. Reactome gene enrichment of the human 
genes showed targeting of genes which are involved in innate immunity, RUNX3 
immune response and migration, integrin cell surface interaction and extracellular 
matrix degradation. As expected the significant viral genes targeted by EBV 
miRNAs were all genes involved in lytic cycle of the virus (these were BALF5 and 
BZLF1). Overall, consistent with the mRNA expression of the high group we 
report EBV miRNAs are also involved in suppressing the host immune system 
and regulating the viral latency in EBVaGC. 
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IV.5 Discussion 
Anywhere between 5-30% of gastric cancer tumors are known to be EBV 
positive, however, the exact role and the mechanism in which the presence of 
this virus might play in the cancer manifestation, progression, or prognosis is not 
clearly understood. Here, we characterize three unique populations of gastric 
cancer based on the expression of level of EBV ncRNAs. We aimed to decipher 
the differences between these populations in terms of molecular signatures on 
the transcriptome level, prognosis and viral miRNA target identification through 
computational pipelines, and target detection modeling.  
We observed a population with high levels of viral non-coding RNAs 
expression ( ≥10000 CPM) with unique host mRNA signature of immune 
dampening ( increase in IL10 signaling and WNT signaling pathways). The 
enrichment of these pathways was in concordance with the literature of EBV 
interaction with host genome, as the virus produces an IL10 homolog (vIL10) 
which interact with the host through similar pathways leading to immune 
dampening in the host [131]. Additionally, previous research which link EBV 
infection to aberrant WNT signaling in epithelial cells, through various genes 
involved in WNT pathway in both Nasopharyngeal cancer (NPC) and stomach 
cancer [132]. The viral genes highly expressed in this populations are mainly 
genes involved with latency II and I EBV life cycle consistent with literature [56]. 
These highly expressed genes were mainly LMP1, LMP2 and EBNA1 genes. 
There were very low levels of lytic genes expressed across the viral genome as 
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well, which is in agreement with a model that some of the stomach epithelial cells 
are potentially in lytic reactivation and shed EBV particles for transmission into 
the tumor microenvironment [133]. Based on our miRNA target prediction 
algorithm of 8 highly expressed miRNAs(ebv-mir-bart22, ebv-mir-bart8-3p, ebv-
mir-bart7-3p, ebv-mir-bart9, ebv-mir-bart10, ebv-mir-bart6-3p, mir-bart11-3p, and 
mir-bart17-3p), these miRNAs are involved in targeting genes involved in the lytic 
reactivation of virus such as BZLF1, BALF1, BRLF1, BXLF1, BALF3, 
BALF1,BXLF2, and BALF2. We also found these viral miRNAs play roles in 
targeting genes involved in host immunity and other genes involved in intra and 
extracellular traffic important to viral lytic reactivation (CRP, SPP1, FKBP10, 
TNFAIp6, DEFA5, NOS2, and APOB, ALPI, SPRR2F2, SPRR2D, ACE 
respectively). Taken together, we believe the high population can represent the 
tumor samples with true EBV latency 1 or 2 EBV infection.  
interestingly the medium population we showed a specific gene 
expression signature in comparison to the high EBVaGC and the EBV negative 
population. Consistent with the finding on adult acute myeloid leukimia (AML), 
medium EBV positive tumors, we find that these tumor samples show elevelated 
defensin pathways and an enrichment involved in the neutrophil deregulation 
[134]. The latter are potentially a result of tumor infiltrating lymphocytes or 
sporadic lytic reactivation[134].  Another interesting observation is an increase in 
FGFR2 genes and pathways in the medium population in comparison to the high 
population. This difference was not observed when the medium population was 
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compared to the low/EBV negative population. To some extent, this clarifies the 
relationship between our classification and the previously shown classification by 
TCGA, and concludes that some of the samples of medium population might 
belong to the CIN subgroup in GC patients [123]. The CIN subgroup is 
associated with a bad outcome in stomach cancer, however, this subgroup 
consists of higher number of stomach tumors [123,130]. Further 
subcategorization of stomach cancers can be, in fact, very important in terms of 
understanding the tumor microenvironment of gastric cancer patients, 
personalized medicine, possible antiviral treatment and outcome prediction of 
patients and, therefore, requires more investigation. 
Our results demonstrate that it is possible that EBV positive status might 
have implications with lower short term survival outcome for GC patients, 
however due to low number of samples we could not confirm our result by 
multiple testing. It is potentially  plausible that EBVaGC patients have lower short 
term prognosis as in other forms of EBV-associated malignancies such as eBL, 
the virus is likely associated with early stages of tumorigenesis[12]. However, our 
cohort was small and a larger cohort of EBV-positive tumors can prove useful to 
better power the study of this phenomenon. 
Finally, we developed a method for modeling the EBV miRNA interaction 
in regards to targeting the host and viral transcriptome. This method looks at the 
interaction of the viral miRNAs with the host or viral transcriptome in 3 distinct 
models of multivariable regression. This method can be adapted for investigating 
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the targets of other miRNAs of various organisms if matching transcriptome data 
is available and drastically reduce the ample number of targets predicted by 
other miRNA target prediction tools.  
In conclusion, we believe use of viral ncRNAs as markers for the EBV 
status can be a robust tool for characterizing EBV infection of stomach cancer. 
We also believe EBV subcategories of stomach cancer needs to be further 
investigated apart from the traditional classifications of GC and can have 
prognostic implication in the survival of stomach cancer patients.  
IV.6 Materials and Methods: 
IV.6.1 Tumor Sample Selection and Analysis  
Tumor miRNA-seq and matching mRNA-seq was obtained from The 
Cancer Genome Atlas (TCGA) (https://cghub.ucsc.edu) through dbGaP (Project 
#13089) and combined [79]. 
IV.6.2 Detection and Quantification of EBV miRNAs 
The miRNA bam reads were extracted  and reverted to fastq. The reads 
were then aligned simultaneously to the human (HG19) and EBV reference 
genomes (NC_007605) to detect best placements using Burrows-Wheeler 
Aligner (bwa-0.7.17). This alignment was done with recommended miRNA-
aligning parameters including zero mismatch for the seed of 8 base pairs, this 
protocol was optimised for miRNA-seq but additionally detected other viral 
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ncRNAs including EBERs [81,82]. We removed cross mapping human miRNAs, 
and only kept miRNA alignments that best aligned to the EBV genome. EBV 
miRNAs and small EBER fragments were then quantified based on their defined 
genomic locations (miRBase version 22) as copies per million (CPM) using 
bedtools and in-house scripts [80,84,85].  
 IV.6.3 Differential Expression Analysis 
Differential expression analysis comparing high versus medium versus 
low/EBV negative samples was performed using the Tuxedo Tools (cufflinks, and 
cuffmerge and cuffdiff). Gene ontology (GO) enrichment  and reactome pathway 
analysis was done using python in house scripts utilizing Panther database 
[113,135].  
IV.6.4 Survival Analysis 
Survival analyses were performed in R utilizing the Kaplan Meier survival 
analysis. 
IV.6.5 MicroRNA(miRNA) Target Prediction 
 In order to assess the targets of viral miRNAs we made 3 models using 
multiples regression statistical method (Y=β0 + β1x1+β1x2+…+ε).  The script 
inputs a gene expression matrix file and a matching miRNA expression matrix file 
from all samples. Henceforth, the user can identify the following: a) the 
miRNA/miRNAs that they want to investigate. b) the type of multiple regression 
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model they want to use ( univariant by inputting and individual miRNA), 
multivariate model by addition of several miRNAs or a synergistic model (miRNA 
A+ miRNA B + miRNA A*miRNA B). The relationship between the miRNA and 
mRNA (β) is assessed for every gene and the P values are calculated for every 
model. We next take all genes which were predicted to be significantly negatively 
associated with the miRNA/miRNAs expression of interest and parse through 
miRanda target prediction performed for each miRNA in relevance to the human 
and EBV transcriptome. Only genes which were predicted as targets of these 
miRNAs in terms of seed matching, conservation and miRNA target duplex 
formation energy are retained [136]. Furthermore, for each miRNA we measure 
targets predicted by miRanda as the highest score ( top 5% of predictions) and 
use them as background for the second round of target prediction. As the 
number of genes are high in the first prediction, achieving FDR correction is not 
plausible. Hereafter, we take the significant genes from the first model and add 
them to the miRanda top prediction list of genes and rerun the prediction with the 
new list of genes to be able to predict the true significance of these miRNAs and 
perform FDR correction within the models. The latter is followed by an overall 
FDR correction across the 3 models explained to find the targets which were 
determined across all models. The code can be found under 
(https://github.com/bailey-lab/Multivariable-Regression-For-miRNA-Target-
Prediction) 
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IV.6.6 Data Visualization  
 Data visualization was performed using a variety of standard tools 
including libraries ggplot2, qqman, prcomp, dplyr and pheatmap were used to 
make the figures. All statistical analysis was done using validated R functions. 
Author Contributions  
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data, and assisted with the analyses and data presentation. M.M supervised all 
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J.B with the help of A.M., C.F. prepared the manuscript. 
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IV.7 Figures 
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Figure 4. 1. Distribution and pattern of expression of EBV across stomach 
cancers.  
A) Each dot is a samples, levels of EBV miRNA and EBERs across TCGA 
stomach cancer tumor samples. The y-axis represents the counts per million 
(CPM) of viral miRNAs and EBERs. The samples with orange background 
10<CPM are those we consider as the low EBV group or EBV negative. The 
samples with 10≤ &< 10000 CPM, with purple background are the EBV positive 
group with medium levels of viral miRNAs and EBERs expressed. FInally, the 
samples with ≥10000 CPM, shown with pink background, of viral miRNA 
expression are considered the high group.B) Principal component analysis (PCA) 
of  all stomach cancer miRNAs and EBERs, each dot is a sample and the PCs 
are separated by miRNA and EBER expression pattern. C) with purple 
background are the EBV positive group with medium levels of viral miRNAs and 
EBERs expressed. FInally, the samples with ≥10000 CPM, shown with pink 
background, of viral miRNA expression are considered the high group. B) 
Principal component analysis (PCA) of  all stomach cancer miRNAs and EBERs, 
each dot is a sample and the PCs are separated by miRNA and EBER 
expression pattern. C) Hierarchical clustering of the pattern of viral miRNAs and 
EBERs expressed across all samples. The y-axis represents individual miRNAs 
and the x-axis represents the samples. The heatmap shows clear separation of 
the high versus medium EBV positive groups represented by blue and orange 
color in the legend. 
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Figure 4. 2. Gene expression difference between the three high, low, and 
medium EBV positive groups. 
 A. Differential expression analysis between EBV high versus medium group. 
Each dot is gene, the x-axis is the log2 (Fold Change) of differential expression 
determined by cuffdiff.  The y-axis is the -log10(p-value) of differential expression 
test. Genes in orange are those with significant q value. A larger view of the q 
value significant genes is provided below the volcano plot. B. Differential 
expression analysis between EBV high versus low group. Genes in pink are 
those with significant q value. A larger view of the q value significant genes is 
provided below the volcano plot for ease of view.C. Differential expression 
analysis between EBV Medium versus low group. Genes in blue are those with 
significant q value based on cufflinks analysis.  
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Figure 4. 3. Expression of EBVl mRNA in high versus medium group.  
A.Expression of EBV mRNAs across samples with high levels of miRNA and 
EBER expression. RPM stands for reads per million n=10. B. Expression of EBV 
mRNAs across samples with medium levels of expression. Only 27 samples out 
of 85 EBV positive medium samples expressed viral mRNA which could detect 
through our pipeline. The grey area represents 0 RPM for the gene in hand. 
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Figure 4. 4. Kaplan Meier survival plot for 3 categories of stomach cancer 
samples based on our grouping of levels of EBV miRNAs and EBERs.  
Total number of tumors with high, medium and low group is shown adjacent to 
the plot. P value is shown on the left corner of every plot. A. 90 day survival 
between EBV positive high versus medium group. B. 1000 day survival 
comparing high to medium EBV positive group. The name of every group is 
shown above the graph concordant with the color. C.90 day survival for medium 
versus low/EBV negative group. D. 1000 days survival for medium to low/EBV 
negative group. E. 90 day survival of high versus EBV negative group (p-value 
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=0.043) F.180 day survival for high versus EBV negative group  (p-value = 
0.051). G. 1000 day survival for high versus EBV negative group. 
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Figure 4. 5. Panel of univariant regressions of miRNA and matching mRNA 
association.  
For every gene the x-axis represents the EBV miRNA level and the y-axis 
represents the gene expression level. Ebv-mir-bart8-1 is the same as ebv-mir-
bart8-3p. The red line represents the linear regression fitted line.  Each dot 
represents a sample. All values have been z scale normalized. The name of the 
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miRNA is printed both on top of the graph and on the x-axis. The name of the 
gene is printed on the y-axis and on top of the graph. Inverse correlation 
represent increase in miRNA levels association with decrease in mRNA level 
(further detail Table 4.5)  
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IV.8 Tables 
Pathway name Entities P-Value 
Entities 
FDR 
#Entities 
found 
#Entities 
total Submitted entities found 
Binding of 
TCF/LEF:CTNNB1 to 
target gene promoters 
0.0001 0.0021 3 10 TCF7;AXIN2 
Interleukin-10 signaling 0.0001 0.0028 5 86 IL10;CXCL10;CCL20 
Repression of WNT 
target genes 0.0001 0.0028 3 16 TCF7;AXIN2 
Formation of the beta-
catenin:TCF 
transactivating complex 
0.0002 0.0091 4 67 TERT;TCF7;AXIN2 
Formation of the 
cornified envelope 0.0004 0.0120 5 138 KRT17 
RUNX3 Regulates 
Immune Response and 
Cell Migration 
0.0010 0.0240 2 10 SPP1 
Erythrocytes take up 
oxygen and release 
carbon dioxide 
0.0024 0.0471 2 16 HBB;HBA2 
TCF dependent 
signaling in response to 
WNT 
0.0029 0.0471 5 216 DKK4;TERT;TCF7;AXIN2 
O-linked glycosylation 0.0030 0.0471 4 132 MUCL1;B3GNT6 
Signaling by WNT 0.0036 0.0471 2 10 DKK4;TERT;TCF7;AXIN2 
O-linked glycosylation 
of mucins 0.0044 0.0489 2 16 MUCL1;B3GNT6 
Erythrocytes take up 
carbon dioxide and 
release oxygen 
0.0049 0.0489 5 216 HBB;HBA2 
O2/CO2 exchange in 
erythrocytes 0.0049 0.0489 4 132 HBB;HBA2 
Degradation of beta-
catenin by the 
destruction complex 
0.0078 0.0704 3 90 TCF7;AXIN2 
Defective GIF causes 
intrinsic factor 
deficiency 
0.0089 0.0714 1 2 GIF 
Table 4. 1. Reactome over represented pathway of high versus medium 
group differentially expressed genes.  
Number of entities represents the number of genes that were present in 
differential expression analysis in the high group. Total number of entities is the 
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total number of genes involved in the particular pathway. P values represent the 
significance of enrichment of the pathways and the False Discovery Rate (FDR) 
is used for P value correction.  
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Pathway name Entities P-Value 
Entities 
FDR 
#En 
found 
#En 
total Submitted entities found 
Formation of the cornified envelope <0.0001 <0.0001 28 138 
SPRR2E;SPRR2F;SPRR2G;JUP;K
RT4;KLK13;KRT23;KRT7;LCE3D;K
RT16;KRT14;PI3;SPRR2A;KRT6C;
SPRR2B;SPRR1A;IVL;SPRR1B;K
RT6A;SPRR2D 
Alpha-defensins <0.0001 0.0001 5 11 PRSS1;DEFA6;DEFA5;PRSS3;PR
SS2 
Chylomicron assembly <0.0001 0.0002 5 14 APOA2;APOC3;APOA1;APOA4;AP
OB 
Regulation of Insulin-like Growth 
Factor (IGF) transport <0.0001 0.0003 11 127 
FGA;TF;KLK1;IGF2;KLK13;GPC3;
APOA2;APOA1;NOTUM;APOB;CH
GB 
Chylomicron remodeling <0.0001 0.0004 5 17 APOA2;APOC3;APOA1;APOA4;AP
OB 
Plasma lipoprotein remodeling <0.0001 0.0009 7 54 CREB3L3;APOA2;APOC3;APOA1;
APOA4;APOB 
Signaling by FGFR2 IIIa TM <0.0001 0.0012 5 24 FGFR2 
Plasma lipoprotein assembly 0.0001 0.0023 5 30 APOA2;APOC3;APOA1;APOA4;AP
OB 
Antimicrobial peptides 0.0001 0.0023 9 123 PRSS1;TF;DEFA6;DEFA5;ITLN1;P
I3;PRSS3;PRSS2;S100A7 
Signaling by FGFR2 in disease 0.0004 0.0076 6 63 FGFR2 
Phospholipase C-mediated cascade; 
FGFR2 0.0006 0.0104 4 25 FGFR2 
FGFR2 ligand binding and activation 0.0007 0.0114 4 26 FGFR2 
Plasma lipoprotein assembly, 
remodeling, and clearance 0.0007 0.0118 7 98 
CREB3L3;APOA2;APOC3;APOA1;
APOA4;APOB 
Defensins 0.0011 0.0151 5 51 PRSS1;DEFA6;DEFA5;PRSS3;PR
SS2 
PI-3K cascade:FGFR2 0.0013 0.0178 4 31 FGFR2 
SHC-mediated cascade:FGFR2 0.0014 0.0186 4 32 FGFR2 
Cell junction organization 0.003 0.0365 6 94 CLDN3;JUP;CLDN15;KRT14;CDH1
7;KRT6A 
Downstream signaling of activated 
FGFR2 0.0035 0.0383 4 41 FGFR2 
Negative regulation of FGFR2 
signaling 0.0035 0.0383 4 41 FGFR2 
IRS-related events triggered by 
IGF1R 0.0037 0.0396 5 68 IGF2;FGFR2 
Post-translational modification: 
synthesis of GPI-anchored proteins 0.0079 0.0712 6 115 
XPNPEP2;GP2;LY6D;LYPD2;ALPI;
ALPPL2 
Signaling by FGFR2 amplification 
mutants 0.0082 0.0734 2 9 FGFR2 
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Assembly of active LPL and LIPC 
lipase complexes 0.0105 0.0841 3 30 CREB3L3;APOA4 
PI3K Cascade 0.0115 0.0918 4 58 FGFR2 
Neutrophil degranulation 0.0133 0.0929 14 480 
PRSS1;ORM1;MME;JUP;DEFA5;O
LFM4;ORM2;CEACAM1;TF;SI;ANP
EP;ABP1;PRSS3;PRSS2;S100A7 
Signaling by Insulin receptor 0.015 0.0982 5 96 FGFR2;INS 
IRS-mediated signalling 0.0159 0.0982 4 64 FGFR2 
Sequestration by antimicrobial 
proteins 0.0164 0.0982 2 13 TF;S100A7 
MECP2 regulates transcription of 
neuronal ligands 0.0164 0.0982 2 13 SST 
Table 4. 2. Reactome over represented pathway of medium group versus 
high group differentially expressed genes. 
 # of En represents the number of genes that were present in differential 
expression analysis in the medium group. Total # of En is the total number of 
genes involved in the particular pathway. P values represent the significance of 
enrichment of the pathways and the False Discovery Rate (FDR) is used for P 
value correction. 
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Pathway	name entities P Value 
entities 
FDR 
#	entities	
found 
#entities	
total Submitted	entities	found 
Binding	of	TCF/LEF:CTNNB1	to	target	
gene	promoters <0.0001 0.0049 2 4 TCF7;AXIN2 
Repression	of	WNT	target	genes 0.0001 0.0098 4 7 TCF7;AXIN2 
Synthesis,	secretion,	and	deacylation	of	
Ghrelin 0.0004 0.026 8 8 GHRL 
Formation	of	the	beta-catenin:TCF	
transactivating	complex 0.0005 0.026 11 13 TERT;TCF7;AXIN2 
Interleukin-10	signaling 0.0015 0.03 2 15 FCER2;CXCL10 
RUNX3	Regulates	Immune	Response	and	
Cell	Migration 0.0015 0.03 1 5 SPP1 
TCF	dependent	signaling	in	response	to	
WNT 0.005 0.1 2 9 DKK4;TERT;TCF7;AXIN2 
Table 4. 3. Reactome over represented pathway of high group versus 
low/EBV negative  group differentially expressed genes.  
# of En represents the number of genes that were present in differential 
expression analysis in the high group. Total # of En is the total number of genes 
involved in the particular pathway. P values represent the significance of 
enrichment of the pathways and the False Discovery Rate (FDR) is used for P 
value correction. 
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Pathway name Entities P value Entities FDR 
#En 
found 
#En 
total Submitted entities found 
Formation of the 
cornified envelope <0.0001 <5.30E-03 12 138 
SPRR2E;LCE3D;SPRR2F;SPRR2G;CE
LA2A;KRT16;KRT14;KRT23;SPRR2B;K
LK12 
Antimicrobial peptides <1.00E-04 <5.30E-03 11 123 
REG3A;PRSS1;BPIFB1;DEFA6;PLA2G
2A;DEFA5;ITLN1;REG3G;PRSS3;PRSS
2;S100A7 
Alpha-defensins <1.00E-04 <5.30E-03 5 11 PRSS1;DEFA6;DEFA5;PRSS3;PRSS2 
Digestion and 
absorption 1.00E-04 5.30E-03 5 24 
LIPF;PNLIPRP1;PNLIPRP2;CLPS;PNLI
P;ALPPL2 
Defensins 2.00E-04 7.00E-03 5 51 PRSS1;DEFA6;DEFA5;PRSS3;PRSS2 
Chylomicron assembly 5.00E-04 1.30E-02 3 14 APOA2;APOA1;APOA4 
Metabolism of fat-
soluble vitamins 5.00E-04 1.40E-02 6 94 
CLPS;RBP2;APOA2;APOA1;APOA4;PN
LIP 
Chylomicron 
remodeling 8.00E-04 1.90E-02 3 17 APOA2;APOA1;APOA4 
Plasma lipoprotein 
remodeling 2.80E-03 5.50E-02 13 30 APOA2;APOA1;APOA4 
Platelet degranulation 3.60E-03 6.70E-02 6 137 FGA;ORM1;SERPINE1;SERPINF2;APO
A1;ORM2 
Plasma lipoprotein 
assembly, remodeling, 
and clearance 
4.10E-03 6.70E-02 5 98 LIPF;APOA2;APOA1;APOA4 
Plasma lipoprotein 
assembly 4.20E-03 6.70E-02 3 30 APOA2;APOA1;APOA4 
Response to elevated 
platelet cytosolic Ca2+ 4.60E-03 7.30E-02 6 144 
FGA;ORM1;SERPINE1;SERPINF2;APO
A1;ORM2 
Neutrophil 
degranulation 3.20E-02 1.30E-01 10 480 
PRSS1;ORM1;HSPA6;DEFA5;RNASE2;
PRSS3;CST6;ORM2;PRSS2;S100A7;C
D177 
Table 4. 4. Reactome over represented pathway of medium group versus 
low/EBV negative  group differentially expressed genes.  
# of En represents the number of genes that were present in differential 
expression analysis in the medium group. Total # of En is the total number of 
genes involved in the particular pathway. P values represent the significance of 
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enrichment of the pathways and the False Discovery Rate (FDR) is used for P 
value correction. The neutrophil deregulation is not not FDR significant, however 
it was close to our cutoff of 0.1 FDR hence it is represented in this table.  
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Gene miRNA 
Model 
P_Valu
e 
Model 
FDR 
miRand
a Score 
R 
squared R 
High to 
Medium 
log2Fold 
Change 
P Value q Value 
LYNX1 ebv-mir-bart8_3p 0.0111 0.0500 140 0.3077 0.5647 2.3785 0.0001 0.0036 
SMOC1 ebv-mir-bart8_3p 0.0048 0.0475 106 0.3654 0.6045 2.0291 0.0001 0.0036 
FKBP10 ebv-mir-bart8_3p 0.0021 0.0419 108 0.4172 0.6459 3.9486 0.0001 0.0036 
ORM2 ebv-mir-bart8_3p 0.0113 0.0500 97 0.3069 0.5540 1.6861 0.0010 0.0421 
ACE ebv-mir-bart8_3p 0.0125 0.0500 125 0.2996 0.5474 1.5753 0.0010 0.0441 
SPRR2D ebv-mir-bart8_3p 0.0320 0.0964 124 0.2350 0.4848 7.1977 0.0001 0.0036 
TGM3 ebv-mir-bart8_3p 0.0441 0.0964 110 0.2066 0.4545 4.2909 0.0001 0.0036 
APOB ebv-mir-bart8_3p 0.0406 0.0964 113 0.2129 0.4614 1.4345 0.0010 0.0441 
ACE ebv-mir-bart22 0.0050 0.0340 99 0.3627 0.6022 1.5753 0.0001 0.0036 
APOB ebv-mir-bart22 0.0125 0.0410 130 0.2997 0.5474 6.7768 0.0001 0.0036 
COL9A3 ebv-mir-bart22 0.0132 0.0410 63 0.2954 0.5435 2.9104 0.0001 0.0066 
LYNX1 ebv-mir-bart22 0.0148 0.0410 78 0.2874 0.5361 2.3785 0.0001 0.0036 
ALPI ebv-mir-bart22 0.0151 0.0410 112 0.2861 0.5349 3.0564 0.0001 0.0036 
Table 4. 5. Targets of viral miRNAs on the human transcriptome based on 
the individual regression model.  
 Model P value and FDR  are calculated for each model. For details refer to 
methods section. The R represent linear association. R square root of 
association.The fold change is calculated through differential expression analysis 
between high versus medium groups. The p value and q value are obtained from 
the differential expression analysis done through cuffdiff.  
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Pathway name Entities p-Value Entities FDR 
#Entities 
found 
#Entities 
total 
Submitted entities 
found 
Scavenging by Class H 
Receptors 0.01 0.07 1 4 APOB 
LDL remodeling 0.01 0.07 1 4 APOB 
Post-translational modification 0.01 0.07 2 94 ALPI 
VLDL assembly 0.01 0.07 1 5 APOB 
Chylomicron clearance 0.01 0.07 1 5 APOB 
VLDL clearance 0.01 0.07 1 6 APOB 
Scavenging by Class B 
Receptors 0.01 0.07 1 6 APOB 
Scavenging by Class F 
Receptors 0.01 0.07 1 7 APOB 
Formation of the cornified 
envelope 0.01 0.07 2 27 SPRR2F;SPRR2D 
Chylomicron assembly 0.01 0.07 1 10 APOB 
Chylomicron remodeling 0.01 0.07 1 10 APOB 
Platelet sensitization by LDL 0.02 0.08 1 17 APOB 
Metabolism of Angiotensinogen 
to Angiotensin 0.02 0.08 1 18 ACE 
Plasma lipoprotein assembly 0.02 0.08 1 19 APOB 
Scavenging by Class A 
Receptors 0.02 0.08 1 19 APOB 
LDL clearance 0.02 0.08 1 19 APOB 
Regulation of TLR by 
endogenous ligand 0.02 0.08 1 19 APOB 
Digestion 0.03 0.08 1 22 ALPI 
Digestion and absorption 0.03 0.09 1 27 ALPI 
Plasma lipoprotein clearance 0.04 0.10 1 33 APOB 
Plasma lipoprotein remodeling 0.04 0.10 1 33 APOB 
Synthesis of PA 0.05 0.10 1 39 ALPI 
NCAM1 interactions 0.05 0.10 1 42 COL9A3 
Retinoid metabolism and 
transport 0.05 0.10 1 44 APOB 
Intra-Golgi traffic 0.05 0.10 1 44 ALPI 
Collagen chain trimerization 0.05 0.10 1 44 COL9A3 
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Table 4. 6. Reactome over represented pathway of miRNA targets on the 
human transcriptome based on individual regression model. 
 # of Entities represents the number of genes that were present in differential 
expression analysis in the medium group. Total # of Entities is the total number 
of genes involved in the particular pathway. P values represent the significance 
of enrichment of the pathways and the False Discovery Rate (FDR) is used for P 
value correction. 
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miRNA P-Value FDR R-squared R miRanda Score 
ebv-mir-bart22 0.0107 0.0020 0.8195 0.9053 93 
ebv-mir-bart22 0.0192 0.0103 0.6934 0.8327 73 
ebv-mir-bart17-3p 0.0046 0.0718 0.7631 0.8736 96 
ebv-mir-bart17-3p 0.0046 0.0718 0.7635 0.8738 152 
ebv-mir-bart6-3p 0.0021 0.0826 0.8155 0.9031 111 
Table 4. 7. Targets of viral miRNAs on the viral transcriptome based on the 
individual regression model.  
Model P value and FDR  are calculated for each model. For details refer to 
methods section. The R represent linear association. R square root of 
association. 
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EBV Gene Function 
BXLF2 /gp61 Membrane Fusion with Epithelial cells, involved with EBV 
fusion 
BALF3 Virion Production During Lytic Phase 
BRLF1 Lytic gene, Disrupts viral latency, Induction of epithelial 
cell senescence 
BALF2 Lytic gene, coactivator of BZLF1 lytic gene 
BALF5 Enhanced lytic replication subunit for EBV's polymerase 
 
Table 4. 8. Targets of viral miRNAs and their functions based on the 
individual regression model. 
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Gene P-Value FDR R R square 
LEFTY1 0.006491773 0.07270244 0.3253 0.570350769 
TGM3 0.016690931 0.07270244 0.3221 0.567538545 
TF 0.017579278 0.07270244 0.3071 0.55416604 
APOB 0.024874874 0.07270244 0.3366 0.580172388 
DEFA5 0.025986338 0.07270244 0.2944 0.542586399 
PNLIPRP2 0.028958838 0.07270244 0.3111 0.557763391 
PLA2G1B 0.03024507 0.07270244 0.2951 0.543231074 
PNLIP 0.030777846 0.07270244 0.2931 0.541387107 
FKBP10 0.031496923 0.07270244 0.2871 0.535817133 
COL9A3 0.034935866 0.07270244 0.3334 0.577408001 
ALPI 0.036797552 0.07270244 0.319 0.56480085 
CYP3A4 0.040694619 0.07270244 0.3208 0.56639209 
DPEP1 0.042986285 0.07270244 0.3617 0.601414998 
NOS2 0.043366925 0.07270244 0.2914 0.539814783 
ACE 0.044085014 0.07270244 0.4286 0.654675492 
APOB 0.045021475 0.07270244 0.3366 0.580172388 
Table 4. 9. Targets of viral miRNAs based on the multivariable regression 
model on the human transcriptome.  
P-value is calculated from the model, FDR is the false discovery rate for the gene 
being identified by the model. R square is he square root of association. R is the 
linear association. 
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gene miRNA p value FDR correction R R square 
BZLF1 ebv−mir−bart17−3p 0.0009 0.0336 0.9960 0.9980 
BXLF1 ebv−mir−bart17−3p 0.0265 0.0942 0.9596 0.9796 
BRLF1 ebv−mir−bart17−3p 0.0096 0.0942 0.9798 0.9898 
BALF5 ebv−mir−bart6−3p 0.0325 0.0975 0.9536 0.9765 
Table 4. 10. Targets of viral miRNAs based on the multivariable regression 
model on the viral transcriptome.  
P-value is calculated from the model, FDR is the false discovery rate for the gene 
being identified by the model. R square is he square root of association. R is the 
linear associat 
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Gene p_value FDR R square R Viral miRNAs 
LOC96610 0.000115236 0.0236 0.6968 0.8347 ebv-mir-bart8-3p & ebv-mir--bart10 
TNFAIP6 0.00037237 0.0313 0.6507 0.8067 ebv-mir-bart22 & ebv-mir--bart10 
CRP 0.001353888 0.0579 0.5915 0.7691 ebv-mir-bart22 & ebv-mir--bart10 
SPP1 0.001412668 0.0579 0.5894 0.7677 ebv-mir-bart22 & ebv-mir--bart10 
Table 4. 11. Targets of viral miRNAs based on the synergistic regression 
model on the human transcriptome.  
P-value is calculated from the model, FDR is the false discovery rate for the gene 
being identified by the model. R square is he square root of association. R is the 
linear association.Viral miRNAs are those which target the genes synergistically. 
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Table 4. 12. Targets of viral miRNAs based on the synergistic regression 
model on the viral transcriptome.  
P-value is calculated from the model, FDR is the false discovery rate for the gene 
being identified by the model. R square is he square root of association. R is the 
linear association.Viral miRNAs are those which target the genes synergistically. 
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Gene miRNA P- value FDR 
LOC96610 ebv-mir-bart8-3p & ebv-mir-bart10 0.0001 0.0048 
TNFAIP6 ebv-mir-bart22 & ebv-mir-bart10 0.0004 0.0153 
BZLF1 ebv−mir−bart-17-3p 0.0009 0.0345 
CRP ebv-mir-bart22 & ebv-mir-bart10 0.0014 0.0528 
SPP1 ebv-mir-bart22 & ebv-mir-bart10 0.0014 0.0537 
FKBP10 ebv-miR-bart8-3p 0.0021 0.0775 
BALF5 ebv-mir-bart6-3p 0.0021 0.0775 
Table 4. 13 Targets of viral miRNAs on both viral and human transcriptome 
after FDR correction across the 3 different models. 
 P-value is calculated from the original model, FDR is the false discovery rate 
across all 3 models. R square is he square root of association. R is the linear 
association. 
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V CHAPTER V: Investigation of EBV variations on EBNA3C gene 
across the eastern and western Africa 
V.1 Abstract: 
 
 Epstein Barr Virus (EBV) is a DNA herpes virus which has co-evolved with 
the human host through primate evolution. EBV was the first virus associated 
with cancer in humans. EBV has two sub-types; subtype 1 EBV prevails as the 
predominant strain throughout the world except in Africa and a few other locales 
where the prevalence of subtype 2 is almost equivalent. In some cases, a single 
patient can manifest both types of EBV. Here, we utilized amplicon sequencing to 
identify EBV causal and geographical viral variations in eBL longitudinal studies. 
Our preliminary results point to variations specific to particular geographical 
regions for the virus. We also found that the the viral strain did not change in the 
plasma of eBL patients, the classic EBV associated tumor, at various time points 
after diagnosis and treatment. Furthermore, the subtype and strain of EBV in the 
plasma and tumor of the eBL patients seem to be identical, with the predominant 
strain/subtype in the plasma ( in terms of quantified observed reads) always 
present in the tumors. 
V.2 Introduction: 
 
Epstein Barr Virus (EBV) is one of the oldest viruses that co-evolved with 
the human host throughout time [137]. More than ninety five percent of the 
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world’s population is positive for EBV, yet the exact mechanisms the virus utilizes 
to activate its virulome, manipulate the host genome, or secure its own survival 
are not clear across viral strains and subtypes [87]. EBV is the first virus 
associated with cancer in humans, particularly endemic Burkitt lymphoma (eBL) 
[138]. EBV has two types; the first type of EBV emerges in patients diagnosed 
with mononucleosis infection and the second type displays prevalence in Africa 
and in patients with compromised immune systems or Human Immunodeficiency 
Virus (HIV) [139].  
It is uncertain why the two types of virus are found in various populations, 
and in some cases, a single patient can manifest both types of the virus at the 
same time [139]. Although EBV in general is genomically quite a stable virus in 
terms of variations, it can manifest a high number of variations in subtype specific 
regions across its genome. The viral genes undergoing the highest levels of 
variations are EBNA3B/C, EBNA2, and LMP1 and LMP2 genes [140]. The genes 
in these regions often interact with the human host and can be detected by the 
host immune system [140]. Hence, it is natural for the the virus to undergo 
variations in these regions and escape host immune detection.  
A small number of studies address the topic of EBV genomic variations in 
eBL holoendemic regions across Africa. Some of these studies show alterations 
within viral genome but not many studies have investigated these variants in 
depth nor has there been any explanation for emergence of such variations 
[141]. The other enigma is the eBL-diagnosed patients show EBV load 
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fluctuations at different time points after their chemotherapy treatment and 
remission. The question persists whether these patients are re-infected with a 
new virus, hence displaying high viral loads. Alternatively, some viral strains are 
more persistent in the host and able to surpass immune surveillance in the host 
during remission. Furthermore, it has not been shown if the virus carries the 
same strain and subtype of EBV in their plasma in comparison to the tumor 
manifestation or not. The latter is important because it could provide information 
about the emergence of the tumor and its persistence after acute infection. 
EBAN3C gene of EBV has been implicated in various interactions with the 
human host and is very important in self regulating the viral latency of EBV. The 
interactions of EBNA 3C gene with the host can be at various levels of regulation. 
For example recruitment of polycomb complex 1 (PRC1) subunit complex BMI1, 
increase in gene repression through recruitment of RBPJ(CBF1) to chromatin 
affecting cell fate and promoting DNA damage and genomic instability [142–144]. 
This gene has also been shown to retain EBV subtype specific and overall hyper 
variant regions across EBV strains [6]. 
 Various methodologies have been utilized in order to look across viral 
genomic regions such as genomic sequencing (GS), Molecular inversion probes 
(MIPs), and amplicon sequencing [145–147]. Amplicon sequencing for specific 
genome regions is very cost effective and useful as it allows for sensitive and 
specific deep sequencing of the genetic variations on the region of interest [145]. 
Additionally, if the subtype of EBV is of interest the traditional EBV polymerase 
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chain reaction (PCR) detection methods might be challenging due to the lack of 
sensitivity of the primers due to prevalence of one subtype of the virus in patients 
with mixed infection [7]. 
Here, we attempt to perform a preliminary study of different variation on 
the EBNA3C (regions with high variations and interactions with host) regions of 
the virus through amplicon sequencing in order to comprehend the strain 
distribution and viral persistence and to decipher the difference between the 
strain and subtype of the virus across our EBV positive African cohort. 
V.3 Results: 
V.3.1 Identification of Reliable Amplicons Through Computational And 
Experimental Design 
 We designed EBV subtype specific, variation based primers on the most 
conserved sites of the viral genome EBNA3C region, and used them as amplicon 
probes. The probes were used for samples with known type 1 and type 2 EBV 
infections (Methods). We employed two known EBV type 1 and type 2 cell lines 
(Namalwa = subtype 1 EBV, Jijoye = subtype 2 EBV [148,149] ) to carry the 
preliminary experiments to check the sensitivity of the method at various mixed 
ratios of the two cell types. The prepared samples were sequenced using 
Illumina MiSeq instrument [150]. The results show an accurate divergence of the 
two types of the virus based on haplotype observation, thus validating the 
method in the two cell lines (Figure 5.1A). We further verified the accuracy of the 
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amplicon sequencing by analyzing twenty four Burkitt lymphoma patient samples 
which we already knew their EBV subtype. The two types of the virus diverged 
accurately through in silico haplotype identification (Figure 5.1B). The two types 
of the virus accurately after computational analysis pipeline for haplotype 
identification using SeekDeep [151]. Overall the primers seemed to have a better 
affinity to subtype 2 of EBV infection, however they could detect subtype 1 
reliability.  
V.3.2 Geographical strains and distributions of EBV across 4 African 
countries 
 In order to understand the subtype specificity and strain specificity of the 
EBV across Africa, we utilized our samples from either blood spots or blood 
isolated ficoll DNA 4 African nations, of which 2 were from east Africa (liberia n= 
23 and Ghana n=26) and 2 from western Africa (Kenya n= 9 and Tanzania n = 
10) (a total of 68 samples). We next performed amplicon sequencing using our 
primers on the EBNA3C region of the virus and went through the SeekDeep 
haplotype identification pipeline to predict the divergence of our samples in terms 
of strains and subtypes of EBV across our samples. We identified 69% of 
Ghanaian samples (n=18/26), 26% of the Liberian samples (n =6/23), 80% of the 
Tanzanian samples (n=8/10) and 100% of Kenyan samples (n=9/9) as EBV 
positive. In agreement with the previous literature on various epitopes on 
EBNA3C across several EBV positive genomes, the results demonstrated that 
for the most part there seems to be three dominant haplotypes on the EBNA3C 
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region where most of the variants carry [152]. However, we could observe 
regional specific variants as well, with some variants specific to the eastern Africa 
and samples and some to western Africa. However, these were not the main viral 
strains observed, this may indicate that although there seems to be reinfection in 
the population (in particular, in the Ghanaian school children population) the most 
prevalent haplotype in the blood spots of these patients seems to be the most 
common (Figure 5.2A). Of the latter we identified 13 subtype 2 EBV haplotypes 
and 28 subtype 1 EBV samples (Figure 5.2B). 
V.3.3 Comparison of Tumor Versus Plasma of the 8 eBL Samples  
 EBV plasma viral load has been extensively used as a prognostic marker 
for detection and outcome prediction of various EBV associated cancers such as 
nasopharyngeal cancer (NPC)and NK/T- cell lymphomas [153,154]. We selected 
8 eBL tumor samples with matching plasma DNA was extracted to perform our 
amplicon sequencing and investigate possible variations across the EBNA3C 
regions of EBV. Consistent with our hypothesis, 6 out of 8 of the samples 
remained in agreement in the EBV strain when comparing the plasma and tumor 
(Figure 5.3A,B). The only tumor which showed two different haplotypes (in 
agreement with the matching plasma) was eBL541. Interestingly, two of the 
plasma samples did not have the same subtype as their matching tumors, of 
which 1 strain showed a 55% presence of a type 2 virus at the same time as a 
subtype I virus (45%). The matching tumor sample was a subtype 1 tumor, 
however as the efficacy of our amplicons is shown to be better for subtype 2, it is 
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very possible that the plasma of the tumor is mainly composed of or has almost 
equal type 1 tumor (Figure 5.C). The next tumor retained both subtypes of the 
tumor but the major subtype was the subtype 1 and we could observe the 
subtype of the tumor as subtype 1 as well (Figure 5.3D). One interesting 
observation which our group previously pointed out in a previous publication[155] 
was that in the two cases where we observed the both subtypes in the plasma, 
subtype 1 seems to be found in the tumor. Hence, subtype 1 might have more 
pathogenic characteristic, which would be interesting to further investigate [8]. 
The latter was consistent with our hypothesis that the main strain in the plasma 
will be observed in the matching tumor. The above suggests presence of 
coinfection of several strains in the patient but deviation towards one type in the 
tumor which is consistent with the observance of more viral diversities in the 
plasma [155].  
V.3.4 Longitudinal Study Across 4 eBL Samples at Different Time Points 
After Remission 
 
 Prior studies on matching plasma and oropharynx epithelial cells in 
patients diagnosed with childhood infectious mononucleosis (IM) at various time 
points have shown consistent viral strain when comparing the variation on the 
LMP1 and EBNA2 EBV genome [155]. In order to investigate if the EBV subtype 
and strain changes in our eBL samples, we looked at 4 EBV positive tumors with 
at least 5 minimum longitudinal time points after tumor diagnosis. We next 
performed amplicon sequencing on these samples using our EBNA-3C 
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amplicons. Consistent with previously performed longitudinal studies, we could 
only identify a few time points with detectable viral loads in the plasma (BL579 = 
3 / 5 time points, BL472 = 4 /5 time points, BL494 = 2 / 5 time points and BL577 
= 2/ 5 time points) as the viral load is known to vary in relative abundance at 
various time points [155]. Furthermore, based on our analysis on the remaining 
samples we observed that the the plasma DNA extracted from the first time point 
has the same viral type and strain, at least on the EBNA 3C region, at various 
time points after initial diagnosis of EBV positive tumor (Figure 5.4A, B).  
V.4 Discussion 
EBV infection and in particular subtype 2 EBV infection is highly prevalent 
in Africa [139]. Some of the main enigmas in EBV field encompass the ways the 
viral variants can lead to more pathogenesis and or difference in remission after 
diagnosis across population [140]. Another topic which needs investigation is 
relevance of particular patterns of variations observed in various geographical 
regions in terms of viral variation on the EBV strains and subtypes [156].  
Here we employ amplicon sequencing on EBNA3C gene of the virus in 
order to investigate the prevalence of variations, and their diversity across 
geographical regions and between diseased state and remission state in eBL 
patients. We first investigated the geographical variation across four African 
populations. We saw potentially 3 major viral haplotypes, followed by multiple 
regional (east versus west Africa) and certain variants specific to particular 
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African countries. It is interesting to investigate the functionality of these 
variations and also run more samples to confirm the latter results. Another 
interpretation of the results is that since majority of these samples (all but Kenya 
samples) were drawn from blood spots and the method of their preservation was 
not optimized for EBV identification. The main strain might just be 
contaminations, and as we see regional variants the true haplotype of these 
samples might be the minor haplotypes amplified in lower levels in these 
samples. Our technique can vastly contribute to understanding the evolution of 
EBV types in various geographical locations of Africa. Such approaches can 
potentially detect EBV subtype specific evolution in worldwide populations and 
further expand our knowledge on the virus based on variant categorization. 
EBV positive plasma viral loads have been used as a prognostic marker 
for pre-screening for NPC and NK/T-cell lymphomas [59,154]. Here we wanted to 
further investigate potential differences in viral subtypes or strains of EBV in 
tumor and plasma of the eBL patients. The results demonstrate that in 7 out of 8 
samples with matching plasma and tumor samples the main subtype has 
consistent subtype as the tumor. We also observed more variation in the plasma 
of the patience in comparison to the tumors [155]. For one sample which we did 
not observe agreement,we believe it might be a consequence of higher affinity of 
our EBNA3C amplicons to the EBV subtype 2. Overall we observe that when the 
two subtypes are present in the plasma the tumor will manifest as a subtype 1 
tumor, hinting to potentially more invasive pathogenicity of this subtype. 
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However, we did not have enough samples to investigate this phenomenon and 
follow-up with a large number of cohort research on this topic will be interesting.  
Finally, consistent with the previous longitudinal studies on plasma of IM 
patients we could not observe any variations after initial diagnosis of EBV 
infection through our remission time point sample of eBL samples [155]. Although 
our results are at a preliminary stage due to a small sample size and some 
technical challenges, they are useful as a stepping stone for further investigation 
of a bigger sample cohort and a more in depth study of these variants in terms of 
pathogenesis capabilities. The latter is important as these variants might be a 
useful tool for possible vaccine design in African population with high levels of 
EBV positive eBL [140]. Furthermore, we have only investigated variations in the 
EBNA3C gene, while there are other subtype specific genes which also have 
interesting characterizations in terms of interaction with the immune system, for 
example LMP1. It would be interesting to decipher the variation on such genes to 
better understand the effects of these variations on the host. 
V.5 Material and Methods: 
V.5.1 Sample Collection and Ethical Approval 
 
Dried blood spot samples were collected from children and adults from 
Liberia, Tanzania and Ghana, and DNA was extracted using Qiagen kit from 
these individuals. This study protocol was reviewed and approved by the 
Institutional Review Board of the NMIMR, University of Ghana. eBL Kenyan 
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Tumor Fine needle aspirates (FNAs) were stained with Giemsa/May-Grünwald 
for morphologic diagnosis by microscopy. eBL longitudinal plasma samples were 
collected from patients at various time points after diagnosis. Ethical approval 
was obtained from the Institutional Review Board at the University of 
Massachusetts Medical School (UMMS) and the Scientific and Ethics Review 
Unit at the Kenya Medical Research Institute. 
V.5.2 Primer Design 
Primers on EBNA3C gene were designed on the most stable site on EBV 
genome while encompassing the most amount of subtype specific variation in 
between the flanking sites across 120 genomes available on NCBI database 
(Figure 4.5A & 5B). Unique molecular barcodes (UMI) were added to the primer 
so it would be possible to pool the samples with other sequencing sample runs 
(Figure 5C). Primer sequences were as following: EBNA3C-N1 Forward:GAC 
TCG CCA AGC TGA AG gcaggggtgatgaaaacag, and EBNA3C-N1 Reverse: 
ACG TGT GCT CTT CCG ATCT tagaagccaatgtcgccaac. The primers were 
designed using primer 3 database. 
V.5.3 Amplicon Sequencing And Processing 
Initial polymerase chain reaction (PCR) was performed using the following 
protocol using Q5 enzyme standard conditions for TM= 60C˚, Q5 5X buffer :5µ, 
Q5 GC enhancer:5µl, Q5 enzyme: 0.25µl, PrimerF:1µl, PrimerR:1µl, dNTP:0.5µl, 
DNA:1µl , H20:11.25µl for a total reaction of 25µl. The products were purified for 
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size separation using AMPure beads. The universal sequencing index primers 
were then added to the purified sequence to prep samples for Miseq sequencing 
(Figure 4.5C). Another round of PCR was performed. Final products were 
purified using AMPure beads and run on a gel to ensure no adapter dimer 
presence. The samples were next pooled and sent for Miseq sequencing at 
University of Massachusetts Medical School Sequencing Core. Amplicon 
sequencing data processing was performed after sticking the paired end reads 
using bcl2fastqv2 and using SEEKDeep tool protocol which allows for clustering 
and accurate detection of base pair and indel difference in amplicon sequencing 
[151]. 
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V.6 Figures 
 
 
 
Figure 5. 1. Accurate divergence of subtype 1 and 2 of EBV positive cell 
lines and tumors.  
A. Bar plot of sensitivity and specificity of EBNA3C primers in terms of 
divergence of samples and the quantification capability of the primers. Jijoye is 
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the subtype 2 cell line, Namalwa is the subtype 1 cell line. Various numbers 
represent the ratio of each cell line mix. For example 95N-5J represents, 95 % of 
the mixed cells are namalwa, and 5% are jijoye. Percentage represents the 
percentage of reads out of total reads which are either subtype 1 (Namalwa) or 
subtype 2 (Jijoye) B. Phylogenetic tree of twenty four eBL tumors with previously 
known subtypes. The tree is the result of alignment of the sequence after 
amplicon sequencing in comparison to the reference subtype 1 and subtype 2 
EBV sequence. Each red dot represent a point of divergence from the original 
ancestor or, in the other words a variation. The tree is a neighbor joining tree with 
100 bootstraps, hence the tree scale is 0.01. 
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Figure 5. 2. Geographical variations across 4 African populations.  
A.Various haplotypes pers sample across 4 African populations.The y-axis 
represents the percentage of reads of every sample. The x-axis shows every 
sample and the country the sample has originated from. The colors represent the 
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haplotype or variation that is observed in a particular sample. Similar colors 
represent similar haplotypes. B. Phylogenetic tree of the different haplotypes 
observed across the population. Reference genomes are the subtype 1 and 
subtype 2 EBV genomes. The hyerarchical tree is a neighbor joining tree. Tree 
scale represents the number of bootstraps, n= 5000. The distance between the 
branches represents the base pair differences observed. 
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Figure 5. 3. Deciphering the differences between the matching tumor and 
plasma of the endemic Burkitt lymphoma (eBL) patients.  
A.The y-axis represents the percentage of reads of every sample. The x-axis 
shows every sample and the country the sample has originated from. The colors 
represent the haplotype or variation that is observed in a particular sample. 
Similar colors represent similar haplotypes. As expected the plasma seems to 
show more variation than the tumor. On the x-axis T represents tumor and P 
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represents plasma. B. Phylogenetic tree of the different haplotypes observed 
across the population. Reference genomes are the subtype 1 and subtype 2 EBV 
genomes. The tree is a neighbor joining tree. Tree scale represents the number 
of bootstraps, n= 5000. The distance between the branches represents the base 
pair differences observed. C. The plasma of eBL534 seems to carry a good level 
of another type 1 strain (The read counts are shown next to the plot on top or on 
the left side). D. eBL557 seems to retain both subtypes of EBV but the tumor 
only carries a subtype 1 EBV (The read counts are shown next to the plot on top 
or on the left side). 
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Figure 5. 4. Longitudinal amplicon sequencing of 4 endemic burkitt 
lymphoma samples (eBL). 
 A. The x-axis represents the percentage of certain haplotypes within a sample. 
Different colors on the bars demonstrate different haplotypes. B. The 
phylogenetic neighbor joining tree represents the divergence of various 
haplotypes on EBNA3C region for these 4 samples. None of the samples 
retained subtype 2 EBV. The branches represent number of base pair 
differences. 2000 bootstraps were used for tree generation. 
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Figure 5. 5. Amplicon sequencing primer design. 
A. Type and strain specific variations across 400 bp of 120 EBV genomes. The 
y-axis is the fractions of total samples carrying similar bases. The x-axis is the 
400 base window which we scanned for on the EBV genome k-mer= 400bp. The 
at most left and right side of the plot which seem to be common in 80 percent of 
samples are the regions that the primer was designed for. B. Phylogenetic tree of 
60 samples across this region. The bootstrap number is 5000 and the tree 
separation shows the divergence over strain and subtype of EBV. C. Primer 
design for amplicon sequencing explained in depth in methods section. 
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VI CHAPTER VI: Conclusion and Future Directions 
VI.1 Introduction: 
 
 Epstein Barr virus (EBV) is one of the most successful viruses to have co-
evolved with its human host [157]. This virus successfully infects B cells, 
epithelial cells, and T cells, and manipulates the host immune surveillance, and 
cellular function to guarantee its own survival in latency inside the human cells 
[158]. EBV was first identified in sub-Saharan Africa in patients who presented 
huge tumors in their jaws and abdomins by Denis Burkitt [159]. As the first virus 
which was associated with cancers, EBV is proposed to be observed mainly in 
endemic Burkitt lymphoma (eBL), Nasopharyngeal cancer (NPC), stomach 
cancer, and large B cell lymphoma (DLBC). However, other cancers have been 
reported to be positive for EBV, by Epstein Barr Virus small RNAs (EBER) 
stastining [160]. Concurrently, reports of EBER negative, EBV positive tumors, 
and the reality of inaccessibility of EBER staining or even performing EBER 
staining for every tumor sample suggests probing other methodologies for 
identifying EBV positive cancers [60]. 
 EBV non-coding RNAs (ncRNAs) in particular microRNAs (miRNAs) are 
expressed at all latencies of viral infection; by comparison, its messenger RNA 
(mRNA) only shows activity in very few latencies, if any [161]. Hence, it is only 
logical to use these viral miRNAs and EBERs for detection of EBV positive 
tumors and it is important to understand the underlying mechanism of EBV 
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infection in tumors. Furthermore, the EBV miRNAs have been so far 
characterized in terms of latency and levels of expression [60]. However, cell 
type specificity of these miRNAs has not been investigated. Previous publications 
have shown presence of EBERs in the tumor tissue but not the matching tissue 
by EBER staining, however they have not investigated the levels of EBV miRNAs 
in the matching normal tissue [60].  
 Single nucleotide polymorphisms (SNPs) on miRNAs have been 
associated with differential processing of miRNA by Drosha and change in the 
affinity and binding of the miRNAs to their target [68]. This phenomenon is being 
extensively studied in mammalian systems [68]. Therfore, it is important to 
investigate the presence of variations on EBV miRNAs as well. 
 It has been quite challenging to computationally assess the roles of EBV 
miRNAs, as most of target detection tools focus on target determination for 
humans, worms, and flies [50]. Furthermore, current tools utilized for viral miRNA 
target detection use seed matching and binding energy as parameters [52,53]. 
Use of matching mRNA sequencing (RNA-seq) data in addition to miRNA-seq to 
determine targets of miRNA has been shown to be an effective method as it 
points to direct correlations between the two [48,49]. A bioinformatics pipeline 
that would identify and predict the targets of miRNAs will be useful as it can help 
uncover the exact roles of these miRNAs in the host. 
 The relationship of EBV as a causal factor in cancers is well established 
[21]. However, the mechanism by which this virus effects cancer outcomes or its 
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role as a prognostic marker has not been as extensively studied. Presence of 
EBV miRNAs has been associated with an increase in tumor aggressiveness 
[93]. In fact in classically associated EBV tumors these miRNAs have been 
reported as a prognostic markers for survival [73,92,162]. However, in depth 
characterization while taking into account the clinical data of each patient across 
cancer subtypes has not been investigated when making such predictions. 
 EBV subtypes 1 and 2 are varying in terms of sequence in several regions 
across the viral genome [6]. These region include deletions on the EBNA2, 
EBNA3 and LMP1 and 2 genes [10]. Additionally, there are certain variations 
along the latter genes which could identify the presence of not only one subtype 
but one strain in comparison to another in cases of co-infection in an individual or 
when comparing regional variations of the virus [7]. Hence, use of these gene 
variations to decipher specific virus subtypes presenting themselves in the tumor 
versus the matching plasma would be useful for understanding the pathogenicity 
of one subtype versus another. 
VI.2 EBV Viral Detection And Characterization 
  We developed a computational pipeline where we utilize miRNA seq data 
from large cancer cohorts patients(n of samples = 8,955), plus their clinical data 
from publicly available data and conservatively detected the levels of EBV 
miRNAs across these datasets. We observe a large proportion of samples 
(10.2% to be precise) were classified as EBV positive through our pipeline. This 
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classification was based on our hypothesis that we except a certain percent of 
samples as active EBV infection, anticipating high levels of viral miRNA and 
EBERs to be expressed in this group(≥10,000 counts per million (CPM)). This 
group composed 0.52% of EBV positive identified tumors in our cohort. The 
second group not previously described in literature was a group of samples 
which express ( 10-10,000 CPM ) of EBV miRNAs. Interestingly the majority of 
the tumors with the exception of few (Wilms tumors and adrenal gland tumors) 
which are tumors with low tumor infiltrating lymphocytes, retained samples 
belonging to medium sub-group. Hence, we hypothesize these populations are 
probably a result of tumor sporadic EBV lytic reactivation. Through our 
categorization, we observed the classically EBV associated cancers showed the 
highest average miRNA and EBER levels (eBL, stomach adenocarcinoma, 
DLBC, and esophageal cancer).  
Subsequently, we characterized the expression patterns of EBV miRNAs 
as both cell-type specific and dependant on overall expression levels through 
principal component analysis (PCA) and hierarchical clustering. These cell type 
specific EBV miRNAs were all expressed at high levels (average miRNA 
expression >1000 CPM) per sample, hence they have the potential to alter their 
targets mRNA level [67]. This is novel and important as we could identify certain 
EBV miRNAs overexpressed in B cells versus epithelial cells and vise versa, and 
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we could characterize and better understand the tumor microenvironment 
through specific viral miRNAs. In vitro confirmation of this population through 
quantitative polymerase chain reaction (qPCR) for EBV miRNAs presence would 
be optimal. Overall, we were able to find a copmutational pipeline for identifying 
and characterizing EBV miRNAs. This pipeline can be potentially adapted to 
detect viral miRNAs of other viruses.  
 We also investigated the overall levels of viral miRNA in 28 tumors (across 
4 cancers) with matching normal tissue. Consistent with the literature, we could 
not identify any EBERs in the normal tissue [60]. Additionally, we saw that the 
levels of viral miRNA and EBERs are significantly higher in the tumor tissue in 
comparison to the normal tissue. 
 For the first time we look at EBV variations across all its miRNAs, by 
allowing 1 ≤or 2 mistmaches in the alignment of our miRNAs. We observed only 
few miRNAs retained mismatches on the seed region (n=4), of which 3 / 4  were 
C>U changes. These variants can potentially be further investigated, in terms of 
how they effect the target mRNA interactions and if they could be a result of 
RNA-editing. The latter is proposed as there has been evidence of the host 
immune system adapting the RNA-editing mechanism as a way to alter the retro 
viral genomes (retrogenomes) [163].  
VI.3 EBV miRNAs levels are associated with adult AML survival 
 We next aimed to investigate potential survival association (positive or 
negative association) comparing the samples we have identified as EBV positive 
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(≤10 CPM) to those which are EBV negative (>10CPM). We could only observed 
significant (P=0.00013 Kaplan Meier, Bonferroni-corrected P=0.02) survival 
association between EBV positive adult Myeloid Leukemia (AML) samples and 
EBV negative samples based on our categorization of samples (adult AML 
association was a negative survival association). This was curious, as EBV had 
never been characterized in AML. Furthermore, no survival association was 
observed for the pediatric AML patients (P= 0.85). We also compared survival in 
correlation to EBV miRNA and EBER levels in all adult AML samples (those we 
categorized as EBV positive or negative across all our cohort). We observed 
overall, that survival decreases as the level of EBV miRNAs and EBERs increase 
(P =9.36e-7). 
 We then aimed to investigate other clinical factors which might influence 
survival in adult AML and have been characterized before. These factors 
included both demographics information of the patients, molecular features 
associated with the tumor, and various blood count information for the patients. 
Hereafter, we predicted the independent risk associated with EBV in adult AML 
patients. We observed that in fact EBV was an independent significant feature for 
lower survival in adult AML tumors (confounding <10%). Furthermore, we made a 
predictive model for EBV risk assessment in relevance to survival of adult AML 
patients using bootstrapping and leave one out cross validation (LOOCV), for 
significant clinical features when adding or without EBV. We observed when EBV 
was added as a feature, the area under the curve (AUC) of the the model 
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increased (AUC= 0.62 without EBV to AUC= 0.72 with EBV). We also remade 
the model using cytogenetics categorization of AML and we consecutively saw 
improvement in the AUC prediction when adding EBV to this model as well (AUC 
0.59 to 0.7 for poor and AUC 0.59 to 0.69 for intermediate outcome category). 
  We further investigated the potential reasoning behind this association. 
We looked at the molecular features of EBV positive tumors versus EBV negative 
tumors, examining gene expression and potential variations in adult AML 
patients. We observed a significant increase (P<0.05 and false discovery rate 
(FDR) <0.1) in genes involved in pathways enriched with neutrophil deregulation, 
reactive oxygen species (ROS) activation, inflammation and increase in viral 
persistence pathways. There were only a few lytic genes expressed from the 
virus, suggesting uncontrolled lytic reactivation. Furthemore, we looked at the 
associated variations and not previously associated variations on genes which 
had previously been associated with AML and EBV infection (on RNA-seq data). 
We did find one variation on the HLA-DRA (rs7195) (Chi-square P =0.03991) 
which could potentially be associated with EBV in our sample set and has been 
characterized in other studies, but we could not further perform FDR correction 
on this variant as our sample cohort was small.  
These results suggested an overall continuous increase in inflammation, 
and neutrophil recruitment in these patients, perhaps resulting in lower survival in 
adult AML patients [164]. Further confirmation of our observation on the adult 
AML samples is required on a bigger dataset. Additionally, it would be useful to 
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have matching genome sequencing of these samples to have further 
confirmation of presence of EBV specific variations in the adult AML patients. 
Overall, our findings of prevalent miRNAs elevated below levels observed in 
controlled infection, provide evidence that EBV may represent an important 
prognostic biomarker and can provide important insight into host immune status 
associated with survival. Extending these findings to peripheral markers and 
determining whether monitoring EBV miRNA levels during the course of disease 
may further predict adverse long-term outcomes, further sutdies are warranted.  
VI.4 Stomach Cancer miRNAs And EBV 
 In order to comprehend the two EBV positive subpopulations (high and 
medium) which we characterized, and better understand the function of EBV 
miRNAs, we investigated the stomach tumors in our pan-cancer cohort. The 
reasoning behind this, was that not only stomach cancer tumors EBV miRNA and 
EBER expression showed a clear bell shaped separation, but we had a large 
number tumors of each of these two populations. Additionally, there are ongoing 
efforts to achieve better subcategorization of gastric cancer based on the tumor 
molecular features [165]. 
 We therefore looked at the differentially expressed genes in each of the 
high, medium and low/EBV negative populations(7.5%(n=34), 68.5% (n=321), 
24% (n=97) respectively). We observed in concordance with our adult AML 
study, that the genes significantly over-represented in medium population 
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(P<0.05, FDR<0.1), were enriched in pathways involving neutrophil deregulation, 
and increase in inflammation. Another interesting characteristic of the medium 
population was the increase in FGFR2 gene expression. This gene has been 
categorized as one of the genes elevated in the chromosomal instability (CIN) 
subgroup of stomach cancers [120,165]. This subgroup is associated with high 
inflammation and not a very good survival prediction [165].The high population 
when compared to both the medium and low/EBV negative population had an 
increase in the IL10 pathway, Wnt signaling pathway and pathways regulating 
EBV endocytosis and exocytosis in agreement with the EBV infection literature 
[158,166]. Further classification of FGFR2 CIN positive population and looking at 
survival differences between the EBV positive and negative populations in this 
sub-group can potentially aid with better categorization of stomach cancer 
tumors. 
 We also looked at the survival differences across the high, medium, and 
low population. We observed that the EBV positive high population might have a 
short term survival disadvantage in comparison to medium and low group 
(P<0.042). However, we could not reach significance for this phenomenon by 
multiple correction test, due to low number of samples.  
 Next, we aimed to identify the roles of EBV miRNAs in the tumor 
microenvironment. This meant we needed to look at miRNAs expressed at a 
level sufficient for them to be able to affect their targets (preferably above 1000 
CPM per miRNA) [67]. Hence, we chose the miRNA in high population 
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(CPM<10,000), which had above an average of 1000 CPM of miRNAs expressed 
in all samples. We next looked at the miRanda [129] target prediction for both 
human and viral target prediction. In addition we developed our own statistical 
method, and a multivariable regression pipeline to identify the targets of these 
viral miRNAs and comprehend how they have effects on the tumor 
microenvironment. We also looked across 3 models of regression and identified 
significant EBV miRNA targets. The results within and across these regression 
models demonstrated an enrichment of the pathways targeted by EBV miRNAs 
on the host, which promoted immune system and golgi trafficking (inhibition of 
viral lytic state). EBV miRNAs targeted lytic genes across their own genome, 
which further clarified that the virus is trying to maintain latency and avoid 
immune recognition. 
The latter fidings supports the hypothesis of presence of two 
subpopulation of EBV positive tumor samples. The population where the tumor is 
undergoing true infection and EBV has actually taken control of the tumor 
microenvironment through its miRNAs and genes. The next population, is 
represented by uncontrolled reactivation of viral lytic phase with high 
inflammation and neutrophil deregulation. Further in vitro verification of this 
population and a bigger EBV positive miRNA and matching mRNA cohort would 
be very useful to confirm the targets of EBV miRNAs. It would also be interesting 
to investigate the short term effect of survival in the high EBV positive group in a 
bigger EBV positive sample cohort. Importantly, deciphering the characterization 
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of the cancer specific effects of the medium EBV population through in vitro 
experiments could clarify virus-host interaction mechanisms. These experiment 
could include knock down and overexpression of particular genes related to 
inflammation resulted by EBV lytic reactivation. These results could prove 
important as the majority (68%) of stomach adenocarcinoma samples seem to 
belong to the medium EBV expression subgroup.  
VI.5 Subtype Specific Variations on EBNA3C EBV Gene 
EBV has two subtypes, these two subtypes diverge the populations which 
carry them [6,7]. Subtype 1: 90% of EBV positive population is distributed across 
the world and 50% of population in Africa, while subtype 2 is only seen in 10% of 
population across the world and 50% in Africa. Subtype 2 is also presented in 
HIV positive patients or patients with weakened immune system [6,7].  
EBNA 3C is an important viral gene which interacts directly with the host 
immune system. EBNA3C has been associated with hypermutation by 
overactivation of  activation induced cytidine deaminase (AID) [21]. We 
developed a subtype and strain specific variation based targeted amplicon 
sequencing EBNA3C primers, from comparison of 120 EBV genomes, and 
investigated the EBV variation while asking three questions: 
1) Are there specific geographical subtype specific variations 
associated with EBV? 
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2) Is the eBL tumor subtype/variation always the same as the one we 
observe in the matching plasma of the patients? 
3) While the eBL EBV positive patients are in remission, does the 
virus strain/subtype remain the same in the plasma or does it alter? 
 Through preliminary results of our amplicon sequencing of samples from 4 
African countries (2 from east Africa: and 2 from west Africa) and analysis of 
these data utilizing SeeKDeep tool [151], we could identify variations specific to 
eastern, in comparison to western Africa (Liberia n=23 ,Ghana n=26 and Kenya 
n= 9, Tanzania n = 10 respectively). We also identified 13 subtype 2 EBV 
haplotypes and 28 subtype 1 EBV samples across the four populations.  
 Next we investigated the subtype of EBV positive eBL tumors versus the 
matching plasma of the same patients. As expected we saw more strains and 
subtypes in the plasma in comparison to the tumor [155]. Overall it seems that in 
all but one of the samples the strain/subtype with the majority of reads in plasma 
would take over the tumor. The exception to this observation was a sample which 
had a mixed infection of plasma of subtype 2 and 1 of EBV where the matching 
tumor is presented as a subtype 1 (same strain) tumor. This can be explained by 
two reasons. 1) The amplicon sequencing primers have a better affinity to 
subtype 2 verus subtype 1 of EBV (this was represented in Figure 5.1A). 2) It has 
been suggested that subtype 1 has more aggressive characterization in terms of 
thost having more pathogenic variations in eBL tumor [8]. Hence, whenever both 
subtypes are present subtype 1 would be observed in the tumor. 
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 Finally, we were interested in understanding possibility of viral reinfection 
during remission time for eBL patients plasma. In concordance with the literature, 
we cannot detect the virus at all of the time points after remission [155]. In the 
remaining time points we observe the same type of virus in the plasma of the 
eBL patients in remission. This suggest the patients did not get reinfected with a 
new EBV strain or subtype. 
 It is important to note that the experiments above were done in a small 
cohort of patients and are preliminary data, while we did develop a protocol for 
answering the 3 mentioned questions, more samples need to be added to this 
cohort for final conclusions to be drawn. Furthermore, after confirmation of these 
results in a bigger sample set it would be interesting to unravel the details of 
these variations. Some of the questions which worth inverstigating are: 
● Are the variations observed across various geographical 
populations functional variants and can they be tied to particular 
environmental features specific to that geographical region? 
● Can we predict the genetics composition of the ancestral strain and 
can we predict why the two EBV subtypes evolved and diverged? 
● Why does EBV subtype one take over the tumor even if subtype 2 
is present in the plasma? 
● Furthemore, if there are always strains with similar variations taking 
over the tumor, what are those variations? 
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 It would be interesting to investigate other viral genes which are known to 
interact with the host genome and retain subtype specific variations and ask 
similar questions by amplicon sequencing. Examples of these genes are LMP1, 
LMP2, EBNA3b, and EBNA2. Overall, targeted amplicon sequencing appears to 
be a robust methodology to identify variations across viral genomes in a 
quantitative and accurate manner. 
VI.6 Conclusion 
 In conclusion, this thesis attempts to unravel a method for detection and 
characterization of EBV positive tumors across various subtypes of cancer in 
terms of survival outcome, viral miRNA target prediction and viral mRNA 
expression through computational methodologies. In addition we perform 
preliminary investigation on EBV EBNA3C gene variations across African cancer 
and non-cancer samples in order to answer fundamental questions about viral 
subtype pathogenesis. We characterized two subpopulations of EBV positive 
tumors (high and medium) based on EBV miRNA and EBER expression. These 
populations demonstrate diverging behaviors inside the host cells. One 
population (EBV high population) can manipulate the host immune system in a 
way to guarantee its own survival by entering latency and avoiding the viral lytic 
phase. This manipulations is thorough viral mRNAs and miRNAs expression 
(latency I and II genes in epithelial cells = EBNA1, LMP1 and LMP2, or in the 
case of eBL latency I genes LMP1 and EBNA1 [8] ). Furthermore, these changes 
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on the host and viral genome could be from a direct result of cell type-specific 
EBV miRNAs expression (Proposed Mechanism Figure 6.1).  
The medium population is a result of sporadic lytic reactivation of the virus 
in the tumor cells. This uncontrolled viral reactivation would in turn cause high 
inflammation either directly or indirectly through the increase in ROS, neutrophil 
deregulation, high inflammation and increase in the levels of MHC-II class 
receptors involved in the fusion of EBV and its entrance to the host cells. In some 
cases when the inflammation is acute it could result in lower survival in cancer 
patients this was observed in adult AML(Figure Proposed Mechanism 6.1).  
An interesting clinical perspective to this research in regards to medium 
EBV positive population would be better categorization of stomach cancer. As 
discussed in chapter IV, FGFR2 gene is significantly overexpressed when 
comparing the high versus medium EBV population. However, this observation is 
not sustained when comparing medium versus low EBV miRNA population. This 
suggests a good number of FGFR2 positive population is present in the EBV 
positive medium population. FGFR2 is overexpressed in ~42% of HER2 positive 
stomach cancer patients, these tumors are categorized as the CIN population 
based on TCGA molecular classification of stomach cancer [123,124]. The latter 
could ultimately point to further categorization of CIN FGFR2 positive subgroup 
to medium EBV positive miRNA, CIN, FGFR2 subgroup. Thus, leading to better 
prognosis for these patients as the CIN, FGFR2 subgroup does not posses good 
survival outcomes [123]. The medium EBV positive miRNA, CIN, FGFR2 patients 
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could manifest a worse or different prognosis outcome, or response to cancer 
treatment due to immune frailty which could be diagnosed by EBV reactivation at 
medium viral miRNA levels in these patients. These patients would then be 
categorized as higher risk patients and proper treatments could be tailored for 
them. An example of such treatments could be anti-inflammatories in addition to 
chemotherapies for CIN FGFR2 stomach cancer patients. The latter could in turn 
help increase the survival of these patients. Furthermore, this method of 
classification and treatment could apply to other forms of cancers, which similar 
to stomach cancer, retain EBV positive medium populations.  
Finally, particular variations and subtypes of EBV might be involved either 
tumorigenicity or progression of cancers. These variations are most likely present 
on genes which interact with the host and those which could be detected by the 
immune system. Based on our priliminary amplicon sequencing results on 
EBNA3C gene and some previous literature EBV subtype 1 seems to posses a 
more tumorigenic characteristic and if both types of virus are present in an 
individual it might be expected that tumor of these patients will be a subtype 1 
EBV positive tumor [8]. In cases where the tumor is a subtype II EBV positive 
tumor, there might be other pathogenic agents involved in the development of 
cancer. This is potentially possible as subtype II tumors are mainly either 
observed in Africa where there is a high prevalence of other viruses, bacteria or 
parasites such as malaria [146]. Other subtype II cases are often observed in 
150 
 
association with cases of human deficiency virus (HIV) positive patients around 
the world [7]. 
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VI.7 Figures 
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Figure 6. 1. Proposed mechanism of EBV infection in tumor B cells and 
epithelial cells based on this thesis.  
In the Medium population there is a sporadic lytic reactivation of an EBV positive 
B cell or epithelial cells. Through which antivirus and antibacterial genes in 
addition to genes involved in inflammation and neutrophil deregulation are 
recruited and the tumor microenvironment will undergo inflammation which could 
in some cases lead to lower survival for cancer patients. There is also an 
increase in the Major histocmpatilbility complex (MHC) type 2 receptors. Note the 
level of viral miRNAs in this population is not high enough to affect host or viral 
miRNA regulation. On the other hand in a high level EBV miRNA infected tumor 
sample. The virus has evolved ways to manipulate the host immune system. The 
graphical representation of the high group displayed how the virus, increases the 
overall signialing of the this pathway by both the virus and host genes to dampen 
the immune system, and inhibits dendritic cell presentation to naive B cells. Wnt 
signaling also increases in this EBV positive subtype leading to increase in 
proliferation of the cells. Abundant levels of viral miRNAs are observed in this 
population where they specifically target host immune cells responsible for 
inflammation and T cell recruitment. Additionally, the virus maintains its latency 
not only by targeting the golgi trafficking of the host by EBV cell types specific 
miRNAs but it will regulates its own genome by these viral miRNA expressions 
as well. 
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